Depletion of cells by CRISPR nuclease

By introducing BEC10 nuclease and homologous directed repair technology with double-stranded DNA paraline cleavage activity, efficient genome editing and HDR editing enrichment in cell populations are achieved in cells, solving the inefficiency and difficulty in separation in the prior art The problem of this achieves 100% editing efficiency and accuracy.

CN119032170APending Publication Date: 2024-11-26BRAIN BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380027910.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-19
Filing Date
2023-01-18
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing CRISPR gene editing techniques are inefficient in cells, especially in difficult-to-transfect cell types such as human primary cells, and existing enrichment methods cannot effectively isolate edited cells.

Method used

By introducing BEC10 nuclease with double-stranded DNA paraline cleavage activity, combined with homologous directed repair (HDR) technology, genome editing is performed at the target locus, and genome editing in the cell population is achieved by specifically depleting unedited cells. and enrich HDR-edited cells.

Benefits of technology

It significantly improves the efficiency and accuracy of genome editing, ensures that all 20 clones are edited by HDR, avoids cell death caused by non-specific DNA breaks, and achieves 100% HDR editing efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005044202500000011
    Figure HDA0005044202500000011
  • Figure HDA0005044202500000021
    Figure HDA0005044202500000021
  • Figure HDA0005044202500000031
    Figure HDA0005044202500000031
Patent Text Reader

Abstract

The present invention relates to a method for genome editing cells at a target locus by homologous directed repair (HDR) within a population of cells and simultaneously enriching HDR genome edited cells within the population of cells. The invention also relates to a method for selectively depleting cells comprising a target locus within a population of cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a method for genome editing cells at a target locus by homology directed repair (HDR) in a cell population and simultaneously enriching cells with HDR genome editing in the cell population, wherein the method comprises: (A) introducing the following into cells in the cell population: one or more nucleic acid molecules, the one or more nucleic acid molecules encoding in an expressible form: (i) a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence of any one of SEQ ID NO: 3; (c) a nucleic acid sequence of any one of SEQ ID NO: 4; (d) a nucleic acid sequence of any one of SEQ ID NO: 5; (e) a nucleic acid sequence of any one of SEQ ID NO: 6; (f) a nucleic acid sequence of any one of SEQ ID NO: 7; (g) a nucleic acid sequence of any one of SEQ ID NO: 8; (h) a nucleic acid sequence of any one of SEQ ID NO: 9; (h) a nucleic acid sequence of any one of SEQ ID NO: 10; (h) a nucleic acid sequence of any one of SEQ ID NO: 11; (h) a nucleic acid sequence of any one of SEQ ID NO: 12; (h) a nucleic acid sequence of any one of SEQ ID NO: 13; (h) a nucleic acid sequence of any one of SEQ ID NO: 14; (h) a nucleic acid sequence of any one of SEQ ID NO: 15; (h) a nucleic acid sequence of any one of SEQ ID NO: 16; (i) a nucleic acid sequence of any one of SEQ ID NO: 17; (i) a nucleic acid sequence of any one of SEQ ID NO: 18; (ii) a nucleic acid sequence of any one of SEQ ID NO: 19; (iii) a nucleic acid sequence of any one of SEQ ID NO: 20; (iv) a nucleic acid sequence of any one of SEQ ID NO: 21; (v) a nucleic acid sequence of any one of SEQ ID NO: NO: 4, 5, 6 or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus; and (a) a second segment that interacts with the CRISPR nuclease of (i), and a nucleic acid molecule comprising, consisting of, or encoding: (iii) a donor template having homology to the target locus; or (A') introducing into cells within a cell population: (i) a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) a second segment comprising a nucleotide sequence complementary to a sequence at a target locus; and (c) a second segment comprising a nucleotide sequence complementary to a sequence at a target locus. NO: 4, 5, 6 or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), a nucleic acid molecule encoding in an expressible form: (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus; and (a) a second segment that interacts with the CRISPR nuclease of (i), and a nucleic acid molecule comprising, consisting of, or encoding: (iii) a donor template having homology to the target locus; or (A") introducing into cells within a cell population: (i) a ribonucleoprotein complex (RNP) comprising or consisting of: a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) a second segment consisting of SEQ ID NO: 3 NO: 4, 5, 6 or 7; (c) an amino acid sequence encoded by a nucleotide sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), the CRISPR nuclease complexed with a guide RNA, the guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus;and (a) a second segment that interacts with a CRISPR nuclease, (ii) a nucleic acid molecule comprising, consisting of, or encoding: a donor template having homology to a target locus; and (B) culturing cells under conditions in which the target locus of cells of a cell population becomes genome-edited by homology directed repair (HDR) and the CRISPR nuclease simultaneously enriches for HDR genome-edited cells within the cell population. ; Background Art

[0002] In this specification, a number of documents including patent applications and manufacturer manuals are cited. The disclosure of these documents, although considered irrelevant to the patentability of the present invention, is incorporated herein by reference in its entirety. More specifically, all cited documents are incorporated by reference to the same extent as each individual document is specifically and individually indicated to be incorporated by reference.

[0003] The genome editing technology CRISPR enables genome editing in a wide range of cells and organisms. CRISPR-based technologies have substantially streamlined targeted gene modifications in different prokaryotic and eukaryotic cells. However, depending on the cell type and the targeted DNA region within the genome, CRISPR can be inefficient, resulting in less than 1% of edited mammalian cells.

[0004] Successful genome editing with CRISPR (or other programmable nucleases) requires three sequential prerequisites: (1) efficient delivery of the CRISPR-encoding gene into target cells (transfection / transduction efficiency); (2) efficient expression of the CRISPR components (CRISPR nuclease and CRISPR-RNA); and (3) targeting of the gene of interest (GOI) by the CRISPR ribonucleoprotein complex and repair of the DNA by the cell's own repair pathways.

[0005] The overall success of genome editing depends on the efficiency of each of these individual steps. Thus, the frequency of successful editing events within a transfected cell population is associated with efficient gene delivery (step 1), high nuclease expression and formation of functional ribonucleoprotein complexes (step 2), and finally the introduction of double-stranded DNA breaks (DSBs) followed by repair of DSBs in the cell (step 3).

[0006] Several methods have been developed to separate subpopulations of cells expressing nucleases, such as CRISPR vectors capable of fluorescence or magnetic activated cell sorting (FACS and MACS). These and other available methods allow enrichment of transfected cells or cells expressing CRISPR nucleases, which is necessary but not sufficient for obtaining edited cells. This is because the expression of nucleases in a given cell does not necessarily mean the formation of a functional CRISPR ribonucleoprotein complex and the fact of the introduction of mutations at the targeted DNA site. Therefore, since these FACS or MACS-assisted methods do not allow immediate enrichment of edited cells, genome editing is still too difficult, particularly in cells that are difficult to transfect (such as human primary cell lines).

[0007] WO 2019 / 202099 describes a genome co-editing method for enriching CRISPR-edited cells, which involves genome editing of genes of interest and LRRC8 genes and the use of blasticidin as a selection marker. Liao et al., Nucleic Acids Res. 2015; 43 (20): e134 describe a related method of co-editing using 6-thioguanine (6TG) as a selection agent and knocking out the (hypoxanthine phosphoribosyltransferase) HPRT gene (encoding hypoxanthine phosphoribosyltransferase) to confer cell 6TG resistance. Although these methods effectively enrich genome-edited cells, they are based on the co-editing of a second gene and a selection marker. Summary of the invention

[0008] Therefore, the present invention aims to provide a technically improved method and means capable of enriching CRISPR-edited cells (step 3 above). As a further advantage, the present invention can achieve genomic target-specific depletion of cells within a cell population by CRISPR nuclease.

[0009] Therefore, the present invention relates in a first aspect to a method for genome editing cells at a target locus by homology directed repair (HDR) in a cell population and simultaneously enriching for HDR genome-edited cells in the cell population, wherein the method comprises: (A) introducing into cells within the cell population: one or more nucleic acid molecules encoding in an expressible form: (i) a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence of any one of SEQ ID NO: 3; NO: 4, 5, 6 or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus; and (a) a second segment that interacts with the CRISPR nuclease of (i), and a nucleic acid molecule comprising, consisting of, or encoding: (iii) a donor template having homology to the target locus; or (A') introducing into cells within a cell population: (i) a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) a second segment comprising a nucleotide sequence complementary to a sequence at a target locus; and (c) a second segment comprising a nucleotide sequence complementary to a sequence at a target locus. NO: 4, 5, 6 or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), a nucleic acid molecule encoding in an expressible form: (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus; and (a) a second segment that interacts with the CRISPR nuclease of (i), and a nucleic acid molecule comprising, consisting of, or encoding: (iii) a donor template having homology to the target locus; or (A") introducing into cells within a cell population: (i) a ribonucleoprotein complex (RNP) comprising or consisting of: a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) a second segment consisting of SEQ ID NO: 3 NO: 4, 5, 6 or 7; (c) an amino acid sequence encoded by a nucleotide sequence that is at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence that is at least 80% identical to the nucleotide sequence of (b), the CRISPR nuclease complexed with a guide RNA, the guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at a target locus; and (a) a second segment that interacts with the CRISPR nuclease;(ii) comprising, consisting of, or encoding a nucleic acid molecule: a donor template having homology to a target locus; and (B) culturing cells in a cell population under conditions in which the target locus of cells becomes genome-edited by homology directed repair (HDR) and the CRISPR nuclease simultaneously enriches for HDR genome-edited cells in the cell population. ;

[0010] Cell colony specifies a group of cells.Cell colony can be heterogeneous or homogeneous, and is preferably homogeneous.Heterogeneous cell colonies include cells of different origins, such as different cell types from different species or sources and / or a species or source (such as body parts).On the contrary, homogeneous cell colonies only include cells from a species or source, and preferably only a cell type or a cell of a body part.

[0011] Genome editing (also referred to as genome engineering) is a type of genetic engineering in which a gene of interest is inserted, deleted, modified or replaced in the genome of a cell. According to a first aspect of the present invention, genome editing uses homology directed recombination (HDR) approach. Compared with non-homologous end joining (NHEJ), HDR is a more accurate mechanism for DSB repair due to the need for higher sequence homology between the damaged and complete donor chains of DNA. If the DNA template used for repair is identical to the original DNA sequence at the DSB, or it can introduce specific mutations into damaged DNA, the process is error-free. Therefore, it should be understood that cells in a cell population carrying a target locus to be genome edited can undergo HDR.

[0012] Genome editing can cause loss-of-function mutations or gain-of-function mutations in the genome of a cell. Loss-of-function mutations (also referred to as inactivation mutations) cause the gene of interest to have less or no function (partial or complete inactivation). When an allele has complete loss of function (complete inactivation), this is also referred to herein as (gene) knockout. The genome editing of a gene of interest is preferably knockout. Gene knockout can be achieved by inserting, deleting, modifying or replacing one or more nucleotides of a gene. Gain-of-function mutations (also referred to as activating mutations) can change a gene of interest so that its effect becomes stronger (enhanced activation) or even replaced by different (e.g., abnormal) functions. Gain-of-function mutations can also introduce new functions or effects that a cell did not have before into a cell. In this case, a new gene can be added to the genome of a cell (insertion) or a gene in a genome can be replaced. Gain-of-function mutations that introduce such new functions or effects are also referred to as gene knock-ins.

[0013] Genome editing via HDR according to the first aspect of the invention relies on (i) a nuclease of the clustered regularly interspaced short palindromic repeats (CRISPR / Cas) system, which is also designated herein as a "CRISPR nuclease", (ii) a guide RNA that mediates the interaction between the CRISPR nuclease and the target locus, which is also referred to herein as a "spacer / protospacer" (note that the spacer binds to the target locus, while the protospacer (or protospacer adjacent motif (PAM)) binds the CRISPR nuclease), and (iii) a donor template with homology to the target locus, which is also referred to herein as an "HDR template".

[0014] CRISPR nucleases (or CRISPR-Cas nucleases or Cas nucleases) are a specific type of programmable nuclease. The CRISPR nuclease used according to the present invention is a so-called BRAIN engineered Cas protein (BEC) nuclease. In more detail, the amino acid sequence of SEQ ID NO: 1, 2 or 3 and the nucleotide sequence of SEQ ID NO: 4, 5 or 6 are the amino acid sequences and nucleotide sequences of Class 2 V-type RNA-guided DNA nucleases of BEC85, BEC67 and BEC10 as disclosed in the international application PCT / EP2021 / 000081. Of the three BEC nucleases, BEC10 is the most preferred. SEQ ID NO: 7 is BEC10 that has been optimized for expression in Escherichia coli (E. coli). Therefore, SEQ ID NO: 7 can also be designated as E. coli BEC10.

[0015] CRISPR-Cas systems have been used for genome editing in prokaryotes and eukaryotes. A small piece of RNA (so-called guide RNA (gRNA) or single guide (sgRNA)) with a short "guide" sequence that attaches (binds) to a specific target sequence of DNA in the genome is created. The genomic target site of the gRNA can be any DNA sequence of 20 nucleotides, provided that it meets two conditions: (i) the sequence is unique compared to the rest of the genome, and (ii) the target is immediately adjacent to the pre-spacer adjacent motif (PAM). The PAM sequence is necessary for target binding, but the exact sequence depends on which CRISPR nuclease is used. CRISPR nucleases and their respective PAM sequences are known in the art (see https: / / www.addgene.org / crispr / guide / #pam-table). Therefore, gRNA also binds CRISPR nuclease (BEC enzyme). As in bacteria, gRNA is used to recognize DNA sequences, and CRISPR nucleases cut DNA at the targeted location. Once the DNA is cut, the cell's own DNA repair mechanisms (NHEJ or HDR) add or delete pieces of genetic material, or change the DNA by replacing existing segments with customized DNA sequences. Therefore, in the CRISPR-Cas system, the CRISPR nuclease causes a double-strand break in the DNA at a site determined by a short (~20 nucleotides) gRNA, which is then repaired in the cell by NHEJ or HDR. The CRISPR-Cas system can be multiplexed by adding multiple gRNAs. It has been shown that, for example, five different simultaneous mutations can be introduced into mouse embryonic stem cells by using five different gRNA molecules and one CRISPR nuclease.

[0016] The design and structure of donor templates suitable for HDR are known in the art. If the repair template is identical to the original DNA sequence at the double-strand break (DSB), or it can introduce very specific mutations into the DNA, then HDR is correct. The three core steps of the HDR approach are: (1) The 5'-end DNA chain is excised at the break to create a 3' overhang. This will serve as both a substrate for the protein required for chain invasion and a primer for DNA repair synthesis. (2) The invading chain can then displace one chain of the homologous DNA duplex and pair with the other chain. This results in the formation of hybrid DNA, called a displacement loop (D loop). (3) The recombinant intermediate can then be decomposed to complete the DNA repair process.

[0017] For example, an HDR template used to introduce a mutation or insert a new nucleotide or nucleotide sequence into a gene needs to have a certain amount of homology around the target sequence to be modified. Homology arms starting at the CRISPR-induced DSB can be used. Typically, the insertion site of the modification should be very close to the DSB, ideally less than 10 bp away if possible. An important point to note is that once the DSB is introduced and repaired, the CRISPR enzyme may continue to cut the DNA. As long as the gRNA target site / PAM site remains intact, the CRISPR nuclease will continue to cut and repair the DNA. This repeated editing may be problematic if a very specific mutation or sequence is to be introduced into the gene of interest. To address this problem, the repair template can be designed in a way that the repair template ultimately blocks further CRISPR nuclease targeting after repairing the initial DSB. Two common ways to block further editing are to mutate the PAM sequence or the gRNA seed sequence. When designing a repair template, consider the size of the expected edit. ssDNA templates (also called ssODN) are typically used for smaller modifications. For each homology arm, small insertions / edits may require as few as 30-50 bases, and the optimal exact number may vary based on the gene of interest. 50-80 base homology arms are typically used. For example, Richardson et al. (Nat Biotechnol. 2016 Mar; 34 (3): 339-44) found that asymmetric homology arms (36 bases distal to the PAM and 91 bases proximal to the PAM) supported up to 60% HDR efficiency. Due to the difficulties that may be associated with the production of ssODNs longer than 200 bases, it is preferred to use dsDNA plasmid repair templates to insert larger inserts such as fluorescent proteins or selection boxes into the gene of interest. These templates can have homology arms of at least 800 bp. In order to increase the frequency of HDR editing based on plasmid repair templates, self-cutting plasmids containing gRNA target sites on both sides of the template can be used. When CRISPR nuclease and suitable gRNA (more than one) are present, the template is released from the vector. In order to avoid plasmid cloning, long dsDNA templates generated by PCR can be used. In addition, Quadros et al. (Genome Biol. 2017 May 17; 18 (1): 92) developed Easi-CRISPR, a technology that allows large mutations and takes advantage of ssODN. To create ssODNs longer than 200 bases, RNA encoding the repair template is transcribed in vitro, and then reverse transcriptase is used to create complementary ssDNA. Easi-CRISPR works well in mouse knock-in models, increasing editing efficiency from 1-10% using dsDNA to 25-50% using ssODN. Although HDR efficiency varies by locus and experimental system, ssODN templates generally provide the highest frequency of HDR editing.

[0018] The target site is not particularly limited and refers to a genomic site of interest present in the genome of the cell to be genomic edited. The target site in the genome specifies mitochondrial DNA or genomic DNA, and preferably genomic DNA. The target site is preferably but not necessarily a gene of interest (or target gene). The target site can also be, for example, a gene regulatory element, such as a promoter region or a cis-regulatory element.

[0019] According to step (A) of the method of the present invention, one or more nucleic acid molecules encoding CRISPR nuclease and guide RNA in an expressible form are introduced into cells within the cell population, and the HDR template is additionally introduced into cells within the cell population directly (in the form of single-stranded or double-stranded DNA) or in an expressible form encoded by a nucleic acid molecule (preferably an expression vector), while according to step (A') of the method of the present invention, the CRISPR nuclease itself (i.e., in the form of protein), a nucleic acid molecule encoding a guide RNA are introduced into cells within the cell population, and the HDR template is additionally introduced into cells within the cell population directly or in an expressible form encoded by a nucleic acid molecule. Alternatively, according to step (A"), the CRISPR nuclease itself (i.e., in the form of a protein) is introduced into cells within the cell population, however, in this case, in the form of a ribonucleoprotein complex (RNP) together with a guide RNA. The RNP is assembled in vitro and can be delivered to cells by methods known in the art, such as electroporation or lipofection. The RNP is capable of cleaving the target site with an efficacy comparable to that of nucleic acid-based (e.g., vector-based) CRISPR nucleases (Kim et al. (2014), Genome Research 24(6):1012-1019). Alternatively, according to step (A"), the HDR template is introduced directly into cells within the cell population or into cells within the cell population in an expressible form encoded by a nucleic acid molecule.

[0020] In the case where the HDR template is in an expressible form encoded by a nucleic acid molecule, the nucleic acid molecule can be a separate nucleic acid molecule or the same nucleic acid molecule encoding a CRISPR nuclease and / or a guide RNA. In the case where the HDR template is introduced directly into the cell, the HDR template can be a linear double-stranded or single-stranded DNA molecule. The linear double-stranded DNA molecule is preferably a linearized PCR product, and the linear single-stranded DNA molecule is preferably a ssODN as described above.

[0021] The nucleic acid molecules used according to the present invention can be inserted into several commercially available vectors. A single vector containing both CRISPR nuclease and gRNA and optionally an HDR template is commercially available, thereby acting as an all-in-one vector. Alternatively, the method of the present invention can be implemented by using two or three vectors containing CRISPR nuclease, gRNA and HDR template. It is also possible to use gRNA and / or HDR template-specific vectors and use cells in which CRISPR nuclease has been integrated into the genome. It is preferred to use an integrated vector expressing gRNA, CRISPR nuclease and optionally an HDR template, because only one vector will be introduced into the cell. Vectors that can express CRISPR nuclease and up to seven gRNAs are described, for example, in Sakuma et al., Sci Rep. 2014; 4: 5400.

[0022] Many single gRNA empty vectors (with and without CRISPR nucleases) are available in the art. Likewise, several empty multiple gRNA vectors are available, which can be used to express multiple gRNAs from a single plasmid (with or without expression of CRISPR nucleases). Finally, vectors that only express CRISPR nucleases are also available (see https: / / www.addgene.org / crispr / empty-grna-vectors / ).

[0023] Vector modification techniques are known in the art, for example, described in Sambrook and Russel, 2001. Typically, the vector may contain more than one origin of replication (ori) and a genetic system for cloning or expression, more than one marker for selection in a host such as antibiotic resistance and more than one expression cassette. Suitable origins of replication include, for example, Col E1, SV40 virus and M13 origins of replication. The nucleic acid sequence inserted into the vector may be, for example, synthesized by standard methods or isolated from a natural source. The connection of the coding sequence to transcriptional regulatory elements and / or to other amino acid coding sequences may be carried out using established methods. Such regulatory sequences are well known to those skilled in the art, and include, but are not limited to, regulatory sequences that ensure the initiation of transcription, the initiation of translation, internal ribosome entry sites (IRES) or 2A joints (Owens, Proc. Natl. Acad. Sci. USA 98 (2001), 1471-1476), and optionally regulatory elements that ensure the termination of transcription and the stability of the transcript. Non-limiting examples of regulatory elements ensuring the initiation of transcription include a translation start codon, an enhancer such as, for example, the SV40 enhancer, an insulator and / or a promoter such as, for example, the cytomegalovirus (CMV) promoter, the elongation factor-1 alpha (EF1-alpha) promoter, the SV40 promoter, the RSV-promoter (Rous sarcoma virus), the lacZ promoter, the chicken β-actin promoter, the CAG-promoter (a combination of the chicken β-actin promoter and the cytomegalovirus immediate-early enhancer), the gai10 promoter, the human elongation factor 1a promoter, the AOX1 promoter, the GAL1 promoter, the CaM-kinase promoter, the lac, trp or tac promoter, the lacUV5 promoter, the Autographa californicamultiple nuclear polyhedrosis virus (AcMNPV) polyhedron promoter or a globin intron in mammalian and other animal cells. Non-limiting examples of regulatory elements that ensure transcriptional termination include V40-poly A sites, tk-poly A sites or SV40, lacZ or AcMNPV polyhedral polyadenylation signals, which will be included downstream of the nucleic acid sequence of the present invention. Additional regulatory elements may include translation enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing, nucleotide sequences encoding secretion signals, or signal sequences that can direct the expressed polypeptide to a cell compartment according to the expression system used. In addition, elements such as replication origins, drug resistance genes, regulators (as part of an inducible promoter) may also be included.

[0024] Means and methods for introducing nucleic acid molecules expressing CRISPR nucleases and / or gRNAs (one or more) and optionally (further) HDR templates into cells are known in the art, and these methods include transducing or transfecting cells.

[0025] Transduction is the process of introducing foreign DNA into cells by viruses or viral vectors. Transduction is a common tool used by molecular biologists to stably introduce foreign genes into the genome of host cells. Usually, a plasmid is constructed in which the gene to be transferred is flanked by viral sequences, and the viral protein uses the viral sequence to recognize the viral genome and package it into viral particles. The plasmid is inserted (usually by transfection) into producer cells together with other plasmids (DNA constructs) carrying the viral genes required for forming infectious virions. In these producer cells, the viral proteins expressed by these packaging constructs bind to the sequences on the DNA / RNA (depending on the type of viral vector) to be transferred and insert them into viral particles. For safety reasons, the plasmids used do not contain all the sequences required for virus formation, so that multiple plasmids need to be transfected simultaneously to obtain infectious virions. In addition, only the plasmids carrying the sequences to be transferred contain signals that allow genetic material to be packaged in virions so that there is no gene encoding viral protein to be packaged. The viruses collected from these cells are then applied to the cells to be changed. The initial stages of these infections mimic natural viral infections and result in expression of the transferred genes and (in the case of lentiviral / retroviral vectors) insertion of the DNA to be transferred into the cell's genome. However, since the transferred genetic material does not encode any viral genes, these infections do not produce new viruses (the viruses are "replication-defective"). In the present case, transduction can be used to generate cells that contain the CRISPR nuclease in their genome in an expressible form.

[0026] Transfection is the process of deliberately introducing naked or purified nucleic acids or purified proteins or assembled ribonucleoprotein complexes into cells. Transfection is usually based on non-viral methods.

[0027] Transfection can be chemical-based transfection. Chemical-based transfection can be divided into the following types: transfection using cyclodextrin, polymers, liposomes, or nanoparticles. One of the cheapest methods is to use calcium phosphate. HEPES buffered saline solution (HeBS) containing phosphate ions is combined with a calcium chloride solution containing the DNA to be transfected. When the two are combined, a fine precipitate of positively charged calcium and negatively charged phosphate will be formed, binding the DNA to be transfected on its surface. The suspension of the precipitate is then added to the cells to be transfected (usually cell cultures grown in a monolayer). Through a process that is not yet fully understood, cells take up some of the precipitate and then take up DNA. This process has become a preferred method for identifying many oncogenes. Other methods use highly branched organic compounds, so-called dendrimers, to bind DNA and transfer it to cells. Another method is to use cationic polymers such as DEAE-dextran or polyethyleneimine (PEI). Negatively charged DNA is bound to polycations, and the complex is taken up by cells via endocytosis. Lipofection (or liposome transfection) is a technique for injecting genetic material into cells via liposomes, which are vesicles that can easily fuse with the cell membrane because they are all made of a phospholipid bilayer. Lipofection generally uses positively charged (cationic) lipids (cationic liposomes or mixtures) to form aggregates with negatively charged (anionic) genetic material. This transfection technique performs the same task as other biochemical procedures using polymers, DEAE-dextran, calcium phosphate, and electroporation in terms of transfer to cells. The efficiency of lipofection can be improved by treating the transfected cells with a mild heat shock. Fugene is a widely used series of proprietary non-liposomal transfection reagents that can directly transfect a wide variety of cells with high efficiency and low toxicity.

[0028] Transfection can also be a non-chemical method. Electroporation (gene electrotransfer) is a popular method in which a transient increase in the permeability of the cell membrane is achieved when cells are exposed to short pulses of a strong electric field. Cell squeezing can deliver molecules to cells by cell membrane deformation. Sonoporation uses high-intensity ultrasound to induce pore formation in the cell membrane. This pore formation is mainly attributed to the cavitation of bubbles interacting with nearby cell membranes because it is enhanced by the addition of ultrasound contrast agents (the source of cavitation nuclei). Optical transfection is a method in which a highly focused laser is used to instantaneously produce tiny (~1 μm diameter) holes in the plasma membrane of the cell. Protoplast fusion is a technique in which the transformed bacterial cells are treated with lysozyme to remove the cell wall. Thereafter, a fusion agent (e.g., Sendai virus, PEG, electroporation) is used to fuse the protoplasts carrying the gene of interest with the receptor target cells.

[0029] Finally, transfection can be a particle-based method. A direct transfection method is a gene gun, in which DNA is coupled to nanoparticles of an inert solid (usually gold) and then "fired" (or particle bombarded) directly into the nucleus of a target cell. Therefore, nucleic acids are delivered at high speeds through membrane penetration, usually connected to microprojectiles. Magnetoresistive or magnetically assisted transfection is a transfection method that uses magnetic force to deliver DNA into target cells. Impalefection is performed by puncturing cells with elongated nanostructures and arrays of such nanostructures, such as carbon nanofibers or silicon nanowires functionalized with plasmid DNA.

[0030] Means for introducing proteins (or peptides) into living cells are known in the art and include, but are not limited to, microinjection, electroporation, lipofection (using liposomes), nanoparticle-based delivery, and protein transduction. Any of these methods may be used in conjunction with step (a'). In this regard, the CRISPR nuclease to be introduced can be isolated from its natural environment or recombinantly produced.

[0031] Liposomes used for lipid transfection are small vesicles made of the same material as the cell membrane (i.e., typically a lipid bilayer made of phospholipids), which can be filled with more than one protein (e.g. Torchilin VP. (2006), Adv Drug Deliv Rev., 58 (14): 1532-55). In order to deliver proteins to cells, the lipid bilayer of the liposome can fuse with the lipid bilayer of the cell membrane, thereby delivering the contained protein to the cell. It is preferred that the liposomes used according to the present invention are composed of cationic lipids. The cationic liposome strategy has been successfully applied to protein delivery (Zelphati et al. (2001). J. Biol. Chem. 276, 35103-35110). As known in the art, depending on the protein (more than one) of interest and the cell type used, the exact composition and / or mixture of the cationic lipids used can be changed (Felgner et al. (1994). J. Biol. Chem. 269, 2550-2561). Nanoparticle-based delivery of Cas9 ribonucleoprotein and donor DNA for inducing homology-directed DNA repair is described, for example, in Lee et al. (2017), Nature Biomedical Engineering, 1: 889-90.

[0032] Protein transduction specifies that protein is internalized into cells from the external environment (Ford et al. (2001), Gene Therapy, 8:1-4). The method relies on the intrinsic properties that a small amount of protein and peptide (preferably 10 to 16 amino acids long) can penetrate the cell membrane. The transduction properties of these molecules can be given to the protein fused with it, and therefore provide an alternative for delivering therapeutic proteins to the gene therapy of target cells. Commonly used proteins or peptides that can penetrate cell membranes are, for example, Drosophila melanogaster antennapedia peptides, herpes simplex virus VP22 proteins, HIV TAT protein transduction domains, peptides derived from neurotransmitters or hormones, or 9xArg tags.

[0033] Microinjection and electroporation are well known in the art, and the skilled person knows how to perform these methods. Microinjection refers to the process of introducing microscopic or critical macroscopic levels of substances into single living cells using a glass micropipette. Electroporation is a significant increase in the conductivity and permeability of the plasma membrane of the cell caused by an externally applied electric field. By increasing the permeability, proteins (or peptides or nucleic acid sequences) can be introduced into living cells.

[0034] CRISPR nucleases can be introduced into cells as active enzymes or as zymogens. In the latter case, the CRISPR nuclease undergoes biochemical changes in the cell (e.g., by hydrolysis to reveal the active site, or by changing conformation to reveal the active site), making the zymogen an active enzyme.

[0035] The term "in an expressible form" means that one or more nucleic acid molecules can encode their components in a form that ensures that the guide RNA and / or HDR template (if encoded) is transcribed and the CRISPR nuclease (if encoded) is transcribed and translated into an active enzyme in the cell.

[0036] Example 3 illustrates the method of the first aspect of the present invention. Here, the BEC10 nuclease according to the present invention and the prior art nuclease spCas9 are used in comparison for a method of genome editing of P. pastoris cells at the target locus by HDR, noting that P. pastoris cells are able to repair dsDNA breaks by NHEJ. The results of the prior art nuclease spCas9 are as expected. The result is a mixture of cells in which the target locus is successfully genome edited by HDR and cells in which the target locus is repaired by NHEJ instead of incorporating an HDR template after the dsDNA breaks introduced by spCas9 at the target locus. On the other hand, the results of the nuclease BEC10 according to the present invention are completely unexpected and technically advantageous. This results in cells in which the target locus is successfully genome edited HDR as expected in all 20 clones obtained. No clones showing repair of dsDNA breaks by NHEJ were obtained. Therefore, the method according to the first aspect of the present invention provides a significant increase in the efficiency of obtaining cells for genome editing by HDR. In Example 3, the efficiency is 100%.

[0037] The results discussed in Example 3, together with the further results in Examples 2, 3 and 5 discussed below in conjunction with the second aspect of the invention, indicate that the BEC nuclease exhibits a novel mode of action that, to the best of the inventors' knowledge, is unknown from any prior art CRISPR nuclease. This novel mode of action enables and forms the basis of various embodiments as described herein.

[0038] This novel mode of action can be described as "collateral cleavage activity of double-stranded DNA". It is known from the prior art that certain CRISPR nucleases can exhibit collateral cleavage activity of single-stranded DNA (ssDNA; Cas 12) or collateral cleavage activity of single-stranded RNA (ssRNA; Cas13); see Shashital (2018), Genome medicine; 10:32. These prior art CRISPR nucleases bind to their target loci via guide RNA, resulting in collateral ssDNA or ssRNA collateral activity. However, since the genome of almost all organisms consists of dsDNA, those prior art CRISPR nucleases are not able to target genomic DNA and are not suitable for genome editing.

[0039] The results in Examples 2, 3 and 5 show that the BEC nucleases according to the present invention exhibit double-stranded DNA collateral cleavage activity. Therefore, once the BEC nucleases are activated by binding to their target loci, substantially all dsDNA within a cell whose genome is to be edited can be cleaved by the BEC nucleases. To the best of the inventors' knowledge, the present disclosure is the first report of a CRISPR nuclease with double-stranded DNA collateral cleavage activity.

[0040] Therefore, it is preferred that the CRISPR nuclease to be used herein is not only structurally defined by showing the required sequence homology to the exact sequence of the BEC nuclease, but is also functionally defined as showing double-stranded DNA paralogous cleavage activity and / or being able to deplete cells of dsDNA breaks introduced by the active BEC nuclease at the target locus through NHEJ repair.

[0041] In conjunction with the method of the first aspect of the present invention, it should be noted that cells in which the target locus is successfully genomic edited by HDR no longer show the target locus because the target locus is replaced by the donor template. Protect these cells from the influence of dsDNA paralogous cutting activity. On the other hand, if the target locus is not eliminated by introducing the HDR template, the BEC nuclease is activated by matching the spacer / pre-spacer sequence and induces dsDNA paralogous cutting. The dsDNA break in the genomic DNA provided in trans is expected to exhaust undesirable cells without the introduction of the HDR template, and due to the paralogous activity, the intrinsic NHEJ repair mechanism of the cell is unable to prevent cell death. Non-specific dsDNA breaks in the genome kill cells.

[0042] According to a preferred embodiment of the first aspect of the present invention, the method further comprises (C) isolating one or more cells, wherein the target locus has been genome edited by homology directed repair (HDR).

[0043] It is emphasized that in Example 3, 20 of the 20 clones and therefore 100% of the clones consisted of cells in which the target locus had been genome edited by HDR rather than by NHEJ. Thus, in the case of the method of the first aspect of the invention, step (C) may be as easy as just collecting one or more cells from the culture plate.

[0044] General means and methods for the separation step from a heterogeneous cell population are known in the art. Non-limiting examples are single cell dilution, laser capture microdissection, manual or automated cell picking, FACS and MACS.

[0045] In single cell dilution, a solution containing cells is diluted in increasing steps until a solution with only single cells is obtained. Laser capture microdissection is a method for isolating specific cells of interest from a microscopic region of a tissue, cell or organism. A laser is coupled to a microscope and focused on a selected cell within a cell population. The focus is made to follow a trajectory predefined by the user by moving the laser or stage of the optics. This trajectory with the selected cell, also called an element, is then excised and separated from the adjacent cells. Manual cell picking is a simple, convenient, and effective method for isolating single cells. The manual cell picking micromanipulator consists of an inverted microscope combined with a micropipette movable by a motorized mechanical stage. Cell picking can also be implemented into automated equipment. Fluorescence activated cell sorting (FACS), a specialized type of flow cytometry with sorting capabilities, is the most sophisticated and user-friendly technique for characterizing and defining different cell types in a heterogeneous cell population based on size, granularity and fluorescence. FACS allows simultaneous quantitative and qualitative multiparameter analysis of single cells. Magnetic activated cell sorting (MACS) is another commonly used passive separation technique to separate different cell types based on their differentiation clusters. MACS has been reported to be able to purify and isolate specific cell populations with >90% purity.

[0046] The present invention also relates to isolated cells obtained by the above method and compositions comprising the cells, wherein the compositions are preferably industrial compositions, diagnostic compositions or pharmaceutical compositions. Pharmaceutical compositions are preferred.

[0047] Industrial compositions are intended for use in industry, including agriculture. For example, cells into which a specific enzyme has been introduced as a gene of interest can be used in chemical production, biofuels, food & beverages, animal feed, cosmetics and consumer products.

[0048] The diagnostic composition is intended for use in diagnosing a disease or condition. For example, cells into which a specific fluorescent protein has been introduced as a gene of interest can be used for diagnosis because they can be detected within an organism or tissue sample.

[0049] The term "pharmaceutical composition" relates to a composition for administration to a patient, preferably a human patient. The pharmaceutical composition of the present invention comprises the above-mentioned cells. It may optionally comprise other molecules that can change the properties of the cells of the present invention, such as stabilizing, regulating and / or activating their functions. The composition is preferably in liquid form, such as (one or more) solutions. The pharmaceutical composition of the present invention may optionally and additionally comprise a pharmaceutically acceptable carrier. Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions such as oil / water emulsions, various types of wetting agents, sterile solutions, organic solvents, etc. Compositions comprising such carriers can be formulated by well-known conventional methods. These pharmaceutical compositions can be administered to a subject at a suitable dose. The dosage regimen will be determined by the attending physician and clinical factors. As is well known in the medical field, the dosage for any one patient depends on many factors, including the patient's size, body surface area, age, specific compound to be administered, sex, time and route of administration, general health, and other drugs administered simultaneously. The therapeutically effective amount for a given situation will be easily determined by routine experiments and is within the skill and judgment of an ordinary clinician or physician. Typically, the regimen for regular administration of the pharmaceutical composition should be 1×10 4 Up to 1×10 8 However, a more preferred dose may be in the range of 1×10 5 Up to 1×10 7 The range is 5 × 10 cells per day, and the most preferred is 5 × 10 5 Up to 5×10 6 cells.

[0050] The length of treatment required to observe changes and the time interval after treatment for response to occur vary depending on the desired effect. The specific amount can be determined by routine experiments known to those skilled in the art.

[0051] According to a preferred embodiment of the first aspect of the present invention, the donor template (i) inserts more than one nucleotide at the target locus, (ii) deletes more than one nucleotide at the target locus, and / or (ii) replaces more than one nucleotide at the target locus.

[0052] This can be achieved by designing the donor template accordingly. As discussed above, the donor template generally includes homology arms that ensure that the donor template can replace the target locus by HDR. Compared with the target site, the sequence between the homology arms can include additional nucleotides or a section (or multiple sections) of nucleotides (more than one) (insertion); compared with the target site, the sequence between the homology arms can lack more than one nucleotide or a section (or multiple sections) of nucleotides (more than one) (deletion), and / or compared with the target site, the sequence between the homology arms can include more than one different nucleotide or a different section (or multiple sections) of nucleotides (more than one) (replacement). The fragment of the inserted nucleotides can include more than one gene or be composed of more than one gene, optionally together with more than one expression control sequence such as a promoter.

[0053] Thus, HDR templates can be used to specifically modify a target locus by adding, deleting and / or substituting more than one nucleotide or a stretch (or stretches) of nucleotides (more than one) as desired.

[0054] According to a further preferred embodiment of the first aspect of the present invention, the donor template comprises or consists of a nucleotide sequence having one or more desired mutations flanked by nucleotide sequences homologous to the target locus.

[0055] The nucleotide sequence homologous to the target locus is also referred to herein as a homology arm. In the case of a double-stranded donor template, the homology arm is preferably 30 to 800 bp, more preferably 300 to 500 bp. In the case of a single-stranded donor template, the homology arm is preferably at least 300 bp, and more preferably at least 800 bp.

[0056] As discussed, sequences having more than one desired mutation between arms may include additions, deletions, and / or substitutions of more than one nucleotide or stretch(s) of nucleotides(s).

[0057] According to another preferred embodiment of the first aspect of the present invention, the method further comprises synchronizing and arresting the cells in S and G2 phases in step (B).

[0058] The step of synchronizing and arresting cells in the S and G2 phases in step (B) can increase the efficiency of HDR-mediated genome editing; see, for example, Lin et al. (2014), eLife; 3: e04766. Preferably, cells are synchronized and arrested in the S phase.

[0059] Cell cycle synchronization techniques are established and reviewed, for example, in Jackman and O'Connor (2011), Curr Protoc Cell Biol; Chapter 8: Unit 8.3.

[0060] In a second aspect, the present invention relates to a method for selectively depleting cells comprising a target locus within a cell population, wherein the method comprises: (A) introducing into cells within the cell population one or more nucleic acid molecules, wherein the one or more nucleic acid molecules encode in an expressible form: (i) a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NOs: 1, 2, or 3; (b) an amino acid sequence encoded by a nucleotide sequence of SEQ ID NOs: 4, 5, 6, or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), and (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at the target locus and (b) a second segment that interacts with the CRISPR nuclease of (i); or (A') introducing into cells within the cell population: (i) a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NOs: 1, 2, or 3; (b) an amino acid sequence encoded by a nucleotide sequence of SEQ ID NOs: 4, 5, 6, or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b). NO: 1, 2 or 3; (b) an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), and one or more nucleic acid molecules encoding in an expressible form: (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus and (b) a second segment that interacts with the CRISPR nuclease of (i); or (A") introducing into cells within a cell population: (i) a ribonucleoprotein complex (RNP) comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), and one or more nucleic acid molecules encoding in an expressible form: (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus and (b) a second segment that interacts with the CRISPR nuclease of (i). NO: 4, 5, 6 or 7; (c) an amino acid sequence encoded by a nucleotide sequence that is at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence that is at least 80% identical to the nucleotide sequence of (b), complexed with a guide RNA, wherein the guide RNA comprises (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at a target locus and (b) a second segment that interacts with a CRISPR nuclease; and (B) culturing cells under conditions wherein the CRISPR nuclease selectively depletes cells within a cell population that comprises the target locus.

[0061] The definitions and preferred embodiments of the first aspect of the present invention apply mutatis mutandis to the second aspect of the present invention, provided that they can be amended to be combined with the second aspect of the present invention.

[0062] At this point it should be noted that the second aspect of the invention uses a CRISPR nuclease and a guide RNA as defined in conjunction with the first aspect of the invention, but without a donor template.

[0063] According to a second aspect of the present invention, the novel mode of action of the BEC nuclease discussed above is used to selectively deplete cells containing specific target loci in a cell population. In Example 2, this is illustrated based on a guide RNA targeting ampicillin resistance of a carrier DNA in an E. coli cell, wherein the carrier DNA also carries kanamycin resistance. In the absence of an HDR template, E. coli cells cannot repair dsDNA breaks such as those introduced into ampicillin resistance because they cannot repair double-stranded DNA breaks by NHEJ. The results of the prior art Cpf1 nuclease are as expected. The E. coli cells obtained are no longer resistant to ampicillin, but are still resistant to kanamycin. The results of the BEC10 nuclease are again unexpected and technically advantageous. The E. coli cells obtained are no longer resistant to ampicillin and kanamycin. These results are explained by the dsDNA paralogous cleavage activity as discussed above, which also adds dsDNA breaks to kanamycin resistance. The results of Example 2 are confirmed by the results in Example 3, wherein no donor template is used. No clones were obtained here because NHEJ repaired cells were eliminated by the BEC10 nuclease and it was not possible to generate HDR repaired cells in the absence of donor template. Likewise Example 5 illustrates the method of the second aspect of the invention by showing that the BEC10 nuclease can be used to selectively, i.e. in a target cell specific manner, deplete mammalian cells.

[0064] Therefore, it is also preferred herein that the CRISPR nuclease to be used herein is not only structurally defined by showing the required sequence homology to the exact sequence of the BEC nuclease, but is also functionally defined as showing double-stranded DNA paralogous cleavage activity and / or being able to deplete cells containing the target locus.

[0065] According to preferred embodiments of the first and second aspects of the present invention, the cells within the population are capable of repairing double stranded DNA breaks by non-homologous end joining (NHEJ).

[0066] As shown in Example 3, cells capable of repairing double-stranded DNA breaks by NHEJ can repair double-stranded DNA breaks such as those introduced by CRISPR nucleases by NHEJ. This is particularly undesirable in the case where genome editing is desired via an HDR template. It has been demonstrated that the BEC nuclease according to the present invention can remove cells in which double-stranded DNA is repaired by NHEJ or prevent the appearance of cells in which double-stranded DNA is repaired by NHEJ in the presence of an HDR template and, notably, in the absence of the template. It is believed that this is achieved by the above-mentioned dsDNA paralogous activity of the BEC nuclease according to the present invention.

[0067] According to further preferred embodiments of the first and second aspects of the present invention, the cells within the population are prokaryotic cells.Alternatively and also preferably, they are eukaryotic cells, and more preferably vertebrate cells, and most preferably mammalian cells.

[0068] The prokaryotic cell is preferably a bacterial cell, such as an E. coli cell or a B. subtilis cell.

[0069] Compared with prokaryotic cells, eukaryotic cells are preferred. Eukaryotic cells may be not only chordate cells or vertebrate cells but also yeast cells such as Pichia pastoris cells or Aspergillus niger cells.

[0070] The vertebrate cell is preferably a cell of a vertebrate (particularly mammalian) cell line, an organoid, a primary cell, a cell derived from a primary cell line, or a pluripotent stem cell.

[0071] Mammalian cell lines are populations of cells from mammals that do not normally proliferate indefinitely, but that, due to mutations (which occur naturally, for example in tumors or by artificial mutagenesis), have avoided normal cellular senescence and instead can remain undergoing division. Thus, the cells can be grown in vitro for long periods of time.

[0072] Organoids are miniaturized and simplified versions of organs produced in vitro in three dimensions that display realistic microscopic anatomy. They are derived from one or a few cells from tissues, embryonic stem cells or induced pluripotent stem cells, which can self-organize in three-dimensional culture due to their self-renewal and differentiation capabilities.

[0073] Primary cells are cells taken directly from living tissue (e.g., biopsy material) and established for in vitro growth. These cells undergo very little population doubling, and therefore are more representative of the major functional components of the tissue from which they are derived than continuous (tumor or artificially immortalized) cell lines, and therefore generally represent a more representative model of the in vivo state. Primary cell lines are cell lines that have been established from primary cells.

[0074] Pluripotent stem cells are cells with the ability of self-renewal by division and the ability of three primary germ cell layers (primary germ cell layer) that develop into early embryos, and therefore develop into all cells of adult body, rather than extraembryonic tissues such as placenta.Embryonic stem cells and induced pluripotent stem cells are pluripotent stem cells.Embryonic stem cells are derived from the inner cell mass of blastocysts, and blastocysts are early stage pre-implantation embryos.Human embryos arrive at the blastocyst stage 4-5 days after fertilization, and they are composed of 50-150 cells in this stage.They are preferably separated from embryos without destroying embryos.Induced pluripotent stem cells (also referred to as iPS cells or iPSC) are pluripotent stem cells of a type that can be directly produced from adult cells.The iPSC technology was pioneered by the laboratory of Shinya Yamanaka in Kyoto, Japan, and they showed in 2006 that the introduction of 4 specific genes encoding transcription factors can convert adult cells into pluripotent stem cells. The generation of iPSCs using Oct3 / 4 and / or factors belonging to the Myc, KIf and Sox factor families is described in WO 2009 / 144008.

[0075] According to another preferred embodiment of the first and second aspects of the present invention, the method is an in vitro or ex vivo method.

[0076] Ex vivo methods are methods performed in the context of a living organism. Similarly, in vitro methods are performed with microorganisms, cells or biomolecules outside of their normal biological context.

[0077] Both in vitro and ex vivo methods exclude methods of surgical or therapeutic treatment of the human or animal body, as well as diagnostic methods practised on the human or animal body.

[0078] The present invention relates in a third aspect to (A) one or more nucleic acid molecules encoding, in an expressible form: (i) a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NOs: 1, 2 or 3; (b) an amino acid sequence encoded by a nucleotide sequence of SEQ ID NOs: 4, 5, 6 or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), and (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus; and (a) a second segment interacting with the CRISPR nuclease of (i); or (A') (i) a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NOs: 1, 2 or 3; (b) an amino acid sequence encoded by a nucleotide sequence of SEQ ID NOs: 4, 5, 6 or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b). NO: 4, 5, 6 or 7; (c) an amino acid sequence encoded by a nucleotide sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), and one or more nucleic acid molecules encoding in an expressible form: (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus; and (a) a second segment that interacts with the CRISPR nuclease of (i); or (A") a ribonucleoprotein complex (RNP) comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) a second segment consisting of SEQ ID NO: 3. NO: 4, 5, 6 or 7; (c) an amino acid sequence encoded by a nucleotide sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), complexed with a guide RNA, wherein the guide RNA comprises (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus; and (a) a second segment that interacts with a CRISPR nuclease, which is used to treat a disease by selectively depleting cells containing a target locus associated with the disease to be treated.

[0079] Also described herein are methods of treating a disease by selectively depleting cells comprising a target locus associated with the disease to be treated, the method comprising administering to a subject in need thereof a therapeutically effective amount of (A) one or more nucleic acid molecules encoding, in an expressible form: (i) a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NOs: 1, 2, or 3; (b) an amino acid sequence encoded by a nucleotide sequence of SEQ ID NOs: 4, 5, 6, or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), and (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at the target locus; and (a) a second segment that interacts with the CRISPR nuclease of (i); or (A') (i) a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NOs: 1, 2, or 3; (b) an amino acid sequence encoded by a nucleotide sequence of SEQ ID NOs: 4, 5, 6, or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b). ID NO: 4, 5, 6 or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), and one or more nucleic acid molecules encoding in an expressible form: (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus; and (a) a second segment that interacts with the CRISPR nuclease of (i); or (A") a ribonucleoprotein complex (RNP) comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) a second segment comprising SEQ ID NO: 3. NO: 4, 5, 6 or 7; (c) an amino acid sequence encoded by a nucleotide sequence that is at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence that is at least 80% identical to the nucleotide sequence of (b), complexed with a guide RNA, wherein the guide RNA comprises (a) a first segment comprising a nucleotide sequence that is complementary to a sequence at a target locus; and (a) a second segment that interacts with a CRISPR nuclease.

[0080] The definitions and preferred embodiments of the first and second aspects of the present invention apply mutatis mutandis to the third aspect of the present invention, provided that they can be amended to be combined with the third aspect of the present invention.

[0081] Diseases that would benefit from selective depletion of cells containing a target locus associated with the disease to be treated are often diseases that are candidates for gene knockdown or knockout therapy.

[0082] The disease that would benefit from selective depletion of cells comprising a target locus associated with the disease to be treated is preferably selected from the group consisting of cystic fibrosis, hemophilia A or hemophilia B with or without inhibitors, thalassemia, anemia, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), epilepsy, lysosomal storage disease, Wilson's disease or Menkes' disease, lysosomal acid lipase deficiency cancer, type 1 or type 2 diabetes, Gaucher's disease, Hurler's disease, adenosine deaminase deficiency, glycogen storage disease), RPE65 deficiency, choroideremia, viral infection, hepatitis B, hepatitis C, HIV, or bacterial or fungal infection.

[0083] In a related aspect, the invention relates to (A) one or more nucleic acid molecules encoding, in an expressible form: (i) a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NOs: 1, 2, or 3; (b) an amino acid sequence encoded by a nucleotide sequence of SEQ ID NOs: 4, 5, 6, or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus and (b) a second segment that interacts with the CRISPR nuclease of (i), and a nucleic acid molecule comprising, consisting of, or encoding: (iii) a donor template having homology to the target locus; or (A') (i) a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NOs: 1, 2, or 3; (b) an amino acid sequence encoded by a nucleotide sequence of SEQ ID NOs: 4, 5, 6, or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b). NO: 4, 5, 6 or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), a nucleic acid molecule encoding in an expressible form: (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus and (b) a second segment that interacts with the CRISPR nuclease of (i), and a nucleic acid molecule comprising, consisting of, or encoding: (iii) a donor template having homology to the target locus; or (A") (i) a ribonucleoprotein complex (RNP) comprising or consisting of: a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) a second segment consisting of SEQ ID NO: 3 IDNO: 4, 5, 6 or 7; (c) an amino acid sequence encoded by a nucleotide sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), wherein the CRISPR nuclease is complexed with a guide RNA, the guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus and (b) a second segment that interacts with the CRISPR nuclease; and a nucleic acid molecule comprising, consisting of, or encoding: (ii) a nucleic acid molecule encoding a donor template having homology to the target locus in an expressible form, which is used to treat a disease by gene therapy.

[0084] Similarly, the present invention relates to a method for treating a disease by gene therapy, the method comprising administering to a subject in need thereof a therapeutically effective amount of (A) one or more nucleic acid molecules encoding in an expressible form: (i) a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NOs: 1, 2 or 3; (b) an amino acid sequence encoded by a nucleotide sequence of SEQ ID NOs: 4, 5, 6 or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus and (b) a second segment that interacts with the CRISPR nuclease of (i), and a nucleic acid molecule comprising, consisting of, or encoding: (iii) a donor template having homology to the target locus; or (A') (i) a CRISPR nuclease comprising or consisting of: (a) SEQ ID NOs: NO: 1, 2 or 3; (b) an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), a nucleic acid molecule encoding in an expressible form: (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus and (b) a second segment that interacts with the CRISPR nuclease of (i), and a nucleic acid molecule comprising, consisting of, or encoding: (iii) a donor template having homology to the target locus; or (A") (i) a ribonucleoprotein complex (RNP) comprising or consisting of: a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; NO: 4, 5, 6 or 7; (c) an amino acid sequence encoded by a nucleotide sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), wherein the CRISPR nuclease is complexed with a guide RNA, wherein the guide RNA comprises (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus and (b) a second segment that interacts with the CRISPR nuclease; and a nucleic acid molecule comprising, consisting of, or encoding: (ii) a nucleic acid molecule encoding a donor template having homology to the target locus in an expressible form.

[0085] In gene therapy, a mutated gene is replaced or a new gene is added to the genome of a subject in need in order to treat a disease. Gene therapy holds promise for treating a wide range of diseases. Non-limiting examples are cancer, cystic fibrosis, heart disease, diabetes, hemophilia, and AIDS.

[0086] The desired therapeutic effect can be achieved by the properties of the donor template. The donor template can be designed, for example, so that a mutant gene is replaced or repaired, or by making the cells more resistant to attack by the immune system or therapeutic antibodies.

[0087] The present invention relates in a fourth aspect to a vector comprising in an expressible form (i) a CRISPR nuclease comprising or consisting of: (a) an amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b), (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus; and (a) a second segment that interacts with the CRISPR nuclease of (i), and (iii) optionally, a donor template having homology to the target locus.

[0088] The definitions and preferred embodiments of the first to third aspects of the present invention apply mutatis mutandis to the fourth aspect of the present invention, as long as they can be amended to be combined with the fourth aspect of the present invention.

[0089] A vector with a donor template is suitable for the method according to the first aspect of the invention, while a vector without a donor template is suitable for the methods according to the first and second aspects of the invention, noting that the donor template can also be provided via a separate expression vector or as a nucleic acid molecule such as a PCR product or ssODN.

[0090] The vector or CRSPR nuclease according to the present invention may also be included in the kit. The kit preferably further comprises one or more of the following: (i) a cell population as defined herein, (ii) a culture medium for culturing these cells, and (iii) instructions for using the kit for genome editing of cells at the target locus by homology directed repair (HDR) in the cell population and simultaneously enriching cells edited by HDR genomes in the cell population, and / or for selectively depleting cells comprising the target locus in the cell population.

[0091] The components of the kit may be packaged individually or in different combinations taking into account the intended use for modifying the nucleotide sequence at the target site in the genome of the cell. The components of the kit may be packaged into, for example, vials, tubes or bags.

[0092] The instructions may be in the form of a leaflet in the packaging, or may be in the form of a web link, barcode or QR code on the packaging.

[0093] In a fifth aspect, the present invention relates to the use of CRISPR nuclease for genome editing of cells at a target locus by homology directed repair (HDR) in a cell population and simultaneously enriching for HDR genome-edited cells in the cell population, and / or for selectively depleting cells comprising a target locus in a cell population, wherein the CRISPR nuclease comprises or consists of: (a) an amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence encoded by a nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence at least 80% identical to the nucleotide sequence of (b).

[0094] The definitions and preferred embodiments of the first to fourth aspects of the present invention apply mutatis mutandis to the fifth aspect of the present invention, as long as they can be amended to be combined with the fifth aspect of the present invention.

[0095] The use is preferably ex vivo or in vitro use.

[0096] As discussed above in conjunction with the first and second aspects of the invention, for the uses of the fifth aspect of the invention - HDR genome editing purposes and cell depletion uses - the CRISPR nuclease according to the invention must be used in combination with a guide RNA as defined above. Additionally, for HDR genome editing uses, a donor template as discussed above is used.

[0097] According to preferred embodiments of all aspects of the invention, the sequence identity of at least 80% is preferably at least 85%, more preferably at least 90%, and most preferably at least 95%.

[0098] The above-mentioned at least 80% sequence identity relative to these SEQ ID NOs is, in increasing preference, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 98%, at least 99% and 100%.

[0099] Preferably, the NCBI BLAST algorithm (Stephen F. Altschul, Thomas L. Madden, Alejandro A. Jinghui Zhang, Zheng Zhang, Webb Miller and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25: 3389-3402) perform amino acid sequence and nucleotide sequence analysis and comparison related to the present invention. The technician knows additional suitable programs to compare nucleic acid sequences.

[0100] Likewise, with respect to this preferred embodiment, it is preferred that the CRISPR nuclease to be used herein is not only structurally defined, but also functionally defined to exhibit double-stranded DNA paralogous cleavage activity. Alternatively or additionally, the CRISPR nuclease may be defined as being capable of depleting cells that repair dsDNA breaks introduced by active BEC nucleases at the target locus by NHEJ (in the case of using an HDR template), or being capable of depleting cells comprising the target locus (in the case of not using an HDR template).

[0101] With regard to the embodiments characterized in the present description, in particular in the claims, it is intended that every embodiment mentioned in a dependent claim be combined with every embodiment of every claim (independent or dependent) to which said dependent claim is dependent. For example, where independent claim 1 refers to three alternatives A, B and C, dependent claim 2 refers to three alternatives D, E and F, and claim 3 is dependent on claims 1 and 2 and refers to three alternatives G, H and I, unless otherwise specifically mentioned, it should be understood that the specification explicitly discloses embodiments corresponding to the following combinations: A, D, G; A, D, H; A, D, I; A, E, G; A, E, H; A, E, I; A, F, G; A, F, H; A, F, I; B, D, G; B, D, H; B, D, I; B, E, G; B, E, H; B, E, I; B, F, G; B, F, H; B, F, I; C, D, G; C, D, H; C, D, I; C, E, G; C, E, H; C, E, I; C, F, G; C, F, H; C, F, I.

[0102] Similarly, and also in those cases where independent and / or dependent claims do not refer to alternatives, it is to be understood that if a dependent claim refers back to multiple prior claims, any combination of subject matter covered thereby is deemed to be explicitly disclosed. For example, where independent claim 1, dependent claim 2 refers back to claim 1, and dependent claim 3 refers back to both claims 2 and 1, it is understood that the combination of the subject matter of claims 3 and 1 is as clearly and explicitly disclosed as the combination of the subject matter of claims 3, 2 and 1. Where there is a further dependent claim 4 referring to any of claims 1 to 3, it is understood that the combination of the subject matter of claims 4 and 1, claims 4, 2 and 1, claims 4, 3 and 1, and claims 4, 3, 2 and 1 is clearly and explicitly disclosed. BRIEF DESCRIPTION OF THE DRAWINGS

[0103] The accompanying drawings show:

[0104] Figure 1 - Schematic diagram of the strategy for visualization of the DNA targeting mechanism by co-transfection of both vectors into E. coli to compare the BEC10 nuclease with that of FnCpf1.

[0105] Figure 2 - Example plate showing E. coli colonies 48 hours after transformation to visualize the different molecular mechanisms of BEC10 compared to FnCpf1.

[0106] Figure 3 -Exemplary culture plate showing Pichia pastoris colonies 48 hours after transformation to visualize the different genome editing mechanisms of BEC10 compared to SpCas9.

[0107] Figure 4 - Target-specific cell depletion A: Negative control: 50 / 50 mixture of HEK-EGFP and HEK-DsRed cells transfected with BEC10 combined with a non-targeting spacer. B: Depletion of EGFP-positive cells using an EGFP-specific spacer sequence to activate the BEC10 nuclease without affecting the viability of EGFP-negative (DsRed-positive) cells. C: FACS analysis showing the distribution of ≈55% EGFP-negative (left peak) and ≈45% EGFP-positive cells (right peak) in the negative control (top graph), and the distribution of more than 98.5% EGFP-negative (left peak) and less than 1.5% EGFP-positive cells (right peak) using a spacer matching the EGFP sequence (bottom graph). DETAILED DESCRIPTION

[0108] The examples illustrate the invention.

[0109] Example 1: Construction of functional genome editing systems for Escherichia coli (BEC10 and FnCpf1) and Pichia pastoris (BEC10 and SpCas9)

[0110] 1.1 CRISPR / BEC-Ec and FnCpf1-Ec vectors for genome editing in Escherichia coli BW25113 Body system.

[0111] The necessary genetic elements for inducible expression of BEC10 or FnCpf1 nucleases and for constitutive expression of guide RNA (gRNA) transcripts are provided on three separate vectors (CRISPR / BEC10-Ec, CRISPR / FnCpf1-Ec, and CRISPR / gRNA-Ec).

[0112] In the following, the construction of CRISPR / BEC10-Ec vector and CRISPR / gRNA-Ec system is described. The CRISPR / FnCpf1-Ec vector system was constructed in a similar manner to the CRISPR / BEC10-Ec vector. BEC10_Coli protein table Design of the carrier

[0113] The synthesized 3696 bp BEC10 nucleotide sequence was codon optimized for expression in E. coli BW25113 using a bioinformatics application provided by the gene synthesis provider GeneArt (Thermo Fisher Scientific, Regensburg, Germany), SEQ ID NO: 7. For protein expression, the resulting synthetic gene was fused to the inducible araC-ParaBAD inducible promoter system (SEQ ID NO: 8) and fdT terminator (SEQ ID NO: 9) (Otsuka & Kunisawa, Journal of Theoretical Biology 97 (1982), 415-436). The final BEC10-E. coli protein expression cassette was inserted into an E. coli shuttle vector containing all the necessary genetic elements for episomal propagation and selection of recombinant E. coli cells by Gibson Assembly Cloning (NEB, Frankfurt, Germany).

[0114] CRISPR / BEC10-Ec Vector System

[0115] The complete nucleotide sequence of the constructed CRISPR / BEC10-Ec vector system is provided as SEQ ID NO: 10.

[0116] CRISPR / FnCpf1-Ec vector system

[0117] The complete nucleotide sequence of the constructed CRISPR / fnCpf1-Ec vector system is provided as SEQ ID NO: 11.

[0118] Design of guide RNA (gRNA) expression vector

[0119] Expression of chimeric gRNAs for targeting specific kanamycin genes by BEC10 or FnCpf1 DNA nucleases was driven by the SacB RNA polymerase II promoter from Bacillus megaterium (SEQ ID NO: 12) (Richhardt et al., Applied Microbiology Biotechnology 86 (2010), 1959-1965) and terminated using the transcriptional T1 and T2 termination regions of the Escherichia coli rrnB gene (SEQ ID NO: 13) (Orosz et al., European Journal of Biochemistry 201 (1991), 653-659). The chimeric gRNA consists of a constant 19 bp BEC family stem-loop sequence (SEQ ID NO: 14 (which also applies to the FnCpf1 nuclease) fused to a kanamycin target-specific 24 bp spacer sequence (SEQ ID NO: 15) located inside the kanamycin resistance gene of the CRISPR / BEC10-Ec or CRISPR / FnCpf1-Ec vector.

[0120] The final gRNA expression cassette was inserted by Gibson Assembly Cloning (NEB, Frankfurt, Germany) into an E. coli shuttle vector containing all necessary genetic elements for episomal propagation and selection of recombinant E. coli cells.

[0121] The construction of the final CRISPR / gRNA-Ec vector system was mediated by Gibson Assembly Cloning (NEB, Frankfurt, Germany).

[0122] The identity of all cloned DNA elements was confirmed by Sanger-Sequencing at LGC Genomics (Berlin, Germany).

[0123] The complete nucleotide sequence of the constructed CRISPR / gRNA-Ec vector system is provided as SEQ ID NO: 16.

[0124] 1.2 E. coli culture and transformation

[0125] Transformation of competent E. coli BW25113 cells

[0126] In brief, a single colony of Escherichia coli BW25113 was inoculated in 5ml LB-Kan medium and incubated at 200rpm on a horizontal shaker at 37°C for 12 to 14 hours. The pre-culture grown overnight was diluted into a fresh 60ml LB medium to an optical density of 0.06 at 600nm (OD600). The inoculated medium was incubated at 30°C on a horizontal shaker at 200rpm until the culture reached an optical density of 0.2 at OD600. 600 μl 20% arabinose was added, and the cells were incubated at 30°C at 200rpm until the culture reached an optical density of 0.5 at OD600. The cells were transferred to a 50ml conical tube and harvested by centrifugation at 4°C for 5 minutes and 4000 × g. The cells from the precipitation of the 50ml culture were resuspended in 60ml water and centrifuged at 4°C for 5 minutes and 4000 × g.

[0127] A washing procedure was performed and the cells were resuspended in 30 ml 10% glycerol after centrifugation for 5 min at 4°C and 4000×g. In a second washing step, the cells were resuspended in 6 ml 10% glycerol after centrifugation for 5 min at 4°C and 4000×g. In a final step, the cells were resuspended in 150 μl 10% glycerol. An aliquot of 25 μl of competent cells was stored at -80°C until use. For the transformation procedure, an aliquot of competent cells was thawed and 50 ng of plasmid DNA was added. The prepared cells were electroporated for 5 ms using 1800 V, 25 μF, 200 Ohm. Subsequently, 975 μL of 10-beta / Stable Outgrowth Medium, and 100 μl of the suspension was plated on selective agar plates.

[0128] 1.3 CRISPR / BEC10-Pp vector system for genome editing in Pichia pastoris

[0129] The necessary genetic elements for constitutive expression and guide RNA (gRNA) transcription of BEC10 are provided in the all-in-one CRISPR / BEC10-Pp vector system.

[0130] Design of BEC10 protein expression cassette

[0131] The synthesized 3696 bp BEC10 nucleotide sequence was codon optimized for expression in yeast cells using a bioinformatics application provided by the gene synthesis provider GeneArt (Thermo Fisher Scientific, Regensburg, Germany), SEQ ID NO: 6. In addition, the DNA nuclease coding sequence was extended 5' by the sequence SEQ ID NO: 17 encoding the SV40 nuclear localization signal (NLS) (Kalderon et al., Cell 39 (1984), 499-509). For protein expression, the resulting synthetic 3723 bp gene was fused to the constitutive and bidirectional Pichia pastoris HTX1 promoter (SEQ ID NO: 18) (Weninger et al., Journal of Biotechnology 235 (2016), 139-149) and the Pichia pastoris AOX1TT terminator (SEQ ID NO: 19) (Weninger et al., Journal of Biotechnology 235 (2016), 139-149). The final BEC10 protein expression cassette was inserted by Gibson Assembly Cloning (NEB, Frankfurt, Germany) into the E. coli / Pichia pastoris shuttle vector pPpT6e (EP 3572512A1), which contains all the necessary genetic elements for episomal propagation and selection of recombinant E. coli and Pichia pastoris cells:

[0132] For vector propagation and selection of recombinant E. coli cells, the plasmid contains a pUC-derived high-copy ColE1 replication origin and a kanMX6 marker gene (SEQ ID NO: 20) that confers kanamycin resistance to Pichia pastoris and E. coli, respectively, under the control of a bifunctional ILV5 / synthetic Em72 promoter (SEQ ID NO: 21) (Weninger et al., Journal of Biotechnology 235 (2016), 139-149). The Pichia autonomous replication sequence 1 (PARS1) (SEQ ID NO: 22) allows episomal replication of the pPpT6e shuttle plasmid in Pichia pastoris cells.

[0133] Design of guide RNA (gRNA) expression cassette

[0134] Ribozyme-based technology was applied to release chimeric gRNAs from RNA polymerase II transcripts for targeting the specific Ade2 gene by the BEC10 DNA nuclease in Pichia pastoris (Gao & Zhao, Journal of Integrative Plant Biology 56 (2014), 343-349). The bidirectional HTX1 RNA polymerase II promoter was used to express gRNAs flanked by 5'-cutting hammerhead (HH) and 3'-cutting hepatitis delta virus (HDV) ribozymes (Weninger et al., Journal of Biotechnology 235 (2016), 139-149).

[0135] The chimeric gRNA consists of a constant 19 bp BEC family stem-loop sequence (SEQ ID NO: 14) fused to an Ade2 target-specific 24 bp spacer sequence (SEQ ID NO: 23). The target spacer sequence was identified in the Pichia pastoris Ade2 gene (SEQ ID NO: 24) downstream of the nuclease BEC10-specific PAM motif 5'-TTN-3'.

[0136] The complete RNA expression cassette consisting of the HTX1 RNA polymerase II promoter and the designed chimeric gRNA flanked by HH / HDV ribozymes was provided as a synthetic gene fragment by GeneArt (Thermo Fisher Scientific, Regensburg, Germany).

[0137] The construction of the integrated CRISPR / BEC10-Pp vector system was completed by cloning the synthetic RNA expression cassette in the prepared E. coli / Pichia pastoris pPpT6e shuttle vector, which contained the BEC10 DNA nuclease expression cassette. The construction of the final CRISPR / BEC10-Pp vector system was mediated by Gibson Assembly Cloning (NEB, Frankfurt, Germany).

[0138] The identity of all cloned DNA elements was confirmed by Sanger sequencing at LGC Genomics (Berlin, Germany).

[0139] CRISPR / BEC10-Pp All-in-One Vector System

[0140] The complete nucleotide sequence of the constructed CRISPR / BEC10-Pp vector system is provided as SEQ ID NO: 25.

[0141] 1.4 CRISPR / SpCas9-Pp vector system for genome editing in Pichia pastoris

[0142] The necessary genetic elements for constitutive expression of SpCas9 (S. pyogenes Cas9) DNA nuclease and for single guide RNA transcription are provided in an all-in-one CRISPR / SpCas9_Pp vector system.

[0143] Design of SpCas9 protein expression cassette

[0144] DNA synthesis of a yeast codon-optimized SpCas9 coding sequence based on the published SpCas9 nucleotide sequence from Streptococcus pyogenes (Deltcheva et al., Nature 471 (2011), 602-607) was ordered from GeneArt (Thermo Fisher Scientific, Regensburg, Germany) (SEQ ID NO: 26) for expression in Pichia pastoris. For nuclear translocation, the SpCas9 DNA nuclease coding sequence was 5' extended by a sequence encoding the SV40 nuclear localization signal (NLS) (SEQ ID NO: 17). Following the protein expression strategy described for the BEC10 DNA nuclease, the resulting synthetic 4134 bp SpCac9 gene was fused to the constitutive and bidirectional Pichia pastoris HTX1 promoter (SEQ ID NO: 18) and Pichia pastoris AOX1TT terminator (SEQ ID NO: 19) (Weninger et al., Journal of Biotechnology 235 (2016), 139-149). The final SpCas9 protein expression cassette was inserted into the E. coli / Pichia pastoris pPpT6e shuttle vector by Gibson Assembly Cloning (NEB, Frankfurt, Germany), which carries the same genetic elements for propagation and selection as have been described for the CRISPR / BEC10-Pp vector system. Design of guide RNA expression (gRNA) cassette

[0145] Ribozyme-based technology was applied to release chimeric gRNAs from RNA polymerase II transcripts for targeting the specific Ade2 gene by SpCas9 DNA nuclease in Pichia pastoris (Gao & Zhao, Journal of Integrative Plant Biology 56 (2014), 343-349). The bidirectional HTX1 RNA polymerase II promoter was used to express gRNAs flanked by 5'-cutting hammerhead (HH) and 3'-cutting hepatitis delta virus (HDV) ribozymes (Weninger et al., Journal of Biotechnology 235 (2016), 139-149).

[0146] The chimeric gRNA consisted of an Ade2 target-specific 20 bp spacer sequence (SEQ ID NO: 27) fused to an 80 bp SpCas9-specific sgRNA sequence (SEQ ID NO: 28). The target spacer sequence was identified in the Pichia pastoris Ade2 gene (SEQ ID NO: 24) downstream of the nuclease SpCa9-specific PAM motif 5'-NGG-3'.

[0147] The complete RNA expression cassette consisting of the HTX1 RNA polymerase II promoter and the designed chimeric gRNA flanked by HH / HDV ribozymes was provided as a synthetic gene fragment by GeneArt (Thermo Fisher Scientific, Regensburg, Germany).

[0148] To generate the final CRISPR / SpCas9-Pp vector system, the synthetic RNA transcription cassette was cloned into the prepared E. coli / Pichia pastoris pPpT6e shuttle vector containing the SpCas9 DNA nuclease expression cassette by Gibson Assembly Cloning (NEB, Frankfurt, Germany). The identity of all cloned DNA elements was confirmed by Sanger sequencing by LGC Genomics (Berlin, Germany).

[0149] CRISPR / SpCas9-Pp integrated vector system

[0150] The complete nucleotide sequence of the constructed CRISPR / SpCas9-Pp vector system is provided as SEQ ID NO: 29.

[0151] 1.5 Design of homology-directed repair template (HDR-template)

[0152] 1998bp Ade2 BEC10 and spCas9 HDR templates are designed to generate 1692bp site-specific deletions in the chromosome Pichia pastoris Ade2 gene by homologous recombination. Successful homologous recombination results in complete Ade2 gene deletion. Within the HDR template, the introduced Ade2 gene deletion is flanked by 1022bp and 976bp sequences homologous to the chromosome target region. The successful recombination event mediated by the designed HDR-template eliminates the PAM and pre-spacer regions already described in the chromosome Ade2 gene to prevent the programmed gRNA / BEC10 or gRNA / spCas9 DNA nuclease complex from targeting the Pichia pastoris genome again. In addition, the introduced gene deletion results in Ade2 mutant clones, which are easily identified by the red color of the colonies because the mutant cells lack adenine and accumulate red purine precursors in their vacuoles (Ugolini et al., CurrGenet (2006), 485-92).

[0153] The complete sequence of the Ade2 HDR-template for BEC10 and SpCas9 is provided as SEQ ID NO:30.

[0154] 1.6 Pichia pastoris culture and transformation

[0155] Preparation of competent Pichia pastoris CBS7435 cells

[0156] Preparation and transformation of competent Pichia pastoris CBS7435 cells were performed as described in Wu & Letchworth, Biotechniques (2014), 36, 152-154. Briefly, a single colony of Pichia pastoris was inoculated in 5 ml YPD medium and incubated at 30 ° C for 6 to 8 hours at 250 rpm on a horizontal shaker. The cells of the preculture were diluted into 100 ml YPD medium to an optical density of 0.0025 at 600 nm (OD600 nm).

[0157] The inoculated culture was incubated overnight at 30°C on a horizontal shaker at 250 rpm until the culture reached an optical density of 1.0 to 2.0 at OD600 nm. The cells were harvested by centrifugation for 5 minutes at room temperature (RT) and 4302 × g. The cell density (cells / mL) of the culture was estimated from the optical density at OD600 nm according to the following relationship: 1 × OD600 nm = 5 × 10 7 For each transformation, 8×10 8 The cells were suspended in 8 mL of 100 mM LiAc, 10 mM DTT, 0.6 M sorbitol and 10 mM Tris-HCl and incubated at room temperature for 30 minutes.

[0158] The cells were then pelleted by centrifugation at room temperature for 5 minutes and 3999 × g and resuspended in 1.5 mL of ice-cold 1 M sorbitol. The cells were transferred to a 1.5 mL microcentrifuge tube, washed three times with 1.5 mL of ice-cold 1 M sorbitol, and finally lysed at approximately 10 °C. 10 Resuspend the cells in 80 μl of 1 M ice-cold sorbitol at a final cell density of 10 cells / mL.

[0159] Transformation of competent Pichia pastoris cells

[0160] An aliquot of the prepared competent cells was mixed with 1 μg of supercoiled plasmid DNA in 5 μL water. For repairing DNA damage induced by CRISPR / BEC10 or CRISPR / Cas9 by homologous recombination, 1.5 μg of linear double-stranded DNA fragments were added to cells. The total volume of the 5 μl DNA solution was not more than that of the DNA solution. The DNA-cell mixture was transferred to a pre-cooled 0.2 cm gap vial (gap vial) and incubated on ice for 5 minutes. The electroporation pulse was applied with 2kV, 25 μF, 200 Ω using the Bio-Rad Gene Pulser Xcell electroporation system (Bio-Rad Laboratories, Munich, Germany). Immediately, the electroporated cells were diluted in 1 mL of ice-cold regeneration medium (0.5 × YPD, 0.5 M sorbitol) and transferred to a 2 ml microcentrifuge tube. After incubation for 1 hour without stirring and incubation for 2 hours at 250 rpm on a horizontal shaker, the transformed cells were plated on appropriate selective agar plates according to the experimental settings.

[0161] Plating of transformed Pichia pastoris cells

[0162] To analyze the efficiency of various gRNA spacers, transformed cells were plated on YPD agar plates containing 200 μg / mL Geneticin (G418) in the absence of any homology repair template and incubated at 30°C for at least 2 days.

[0163] Ade2 gene disruption and induced red phenotype of mutant Pichia pastoris cells by BEC10-gRNA- and Cas9-gRNA-mediated integration of co-transformed homologous repair templates in the Ade2 target gene were visualized using a simple colony color filter assay: Transformed cells were plated on NC transfer membrane filters (Merck Chemicals, Darmstadt, Germany) and applied directly to the surface of YPD agar plates supplemented with 200 μg / mL geneticin (G418) and 50 μg / mL adenine. After incubation at 30°C for at least 2 days, the filters with growing cells were transferred to minimal medium agar plates supplemented with 200 μg / mL geneticin (G418) and 5 μg / mL adenine.

[0164] Example 2: Vector targeting in E. coli to demonstrate novel DNA targeting mechanism of BEC family nucleases compared to FnCpf1

[0165] To demonstrate the novel DNA targeting mechanism of BEC family nucleases, experiments were performed using two different vectors co-transformed into E. coli. In two different approaches, a CRISPR / BEC10-Ec vector or a CRISPR / FnCpf1-Ec vector was co-transformed with a CRISPR / gRNA-Ec vector that included a spacer sequence targeting the ampicillin resistance gene located on the CRISPR / BEC10-Ec vector or the CRISPR / FnCpf1-Ec vector (schematic diagram of the experimental setup is shown in Figure 1 As shown). Using a nuclease with classical DNA targeting activity (double-strand break), activation of the CRISPR nuclease will linearize the CRISPR / BEC10-Ec or CRISPR / FnCpf1-Ec vector, resulting in the destruction of the open reading frame of the ampicillin resistance gene and preventing the propagation of the vector. Therefore, due to the deletion of the ampicillin resistance gene located on the CRISPR / BEC10-Ec or CRISPR / FnCpf1-Ec vector, the cell will become sensitive to ampicillin, but still resistant to kanamycin because the kanamycin resistance gene located on the CRISPR / gRNA-Ec vector is still intact.

[0166] To directly compare the DNA targeting mechanisms of BEC family (BEC10) and classical (FnCpf1) nucleases, the following experiments were performed:

[0167] 1. Co-transform the CRISPR / BEC10-Ec vector and the CRISPR / gRNA-Ec vector into E. coli cells and grow / select on plates containing ampicillin & kanamycin and plates containing kanamycin only.

[0168] 2. The CRISPR / FnCpf1-Ec vector and the CRISPR / gRNA-Ec vector were co-transformed into E. coli cells and grown / selected on plates containing ampicillin & kanamycin and plates containing kanamycin only.

[0169] 3. Negative control (NC) experiments for settings 1 and 2 were performed using the same experimental approach, but with a nonsense spacer sequence (not matching a sequence in either the vector or the E. coli genome) in the CRISPR / gRNA-Ec vector.

[0170] All plates were visually evaluated by counting the number of growing colonies.

[0171] result

[0172] All experiments were performed in 5 biological replicates, and the results obtained from these replicates were combined to evaluate the DNA targeting mechanism of BEC10 compared to FnCpf1 (Exemplary plates are shown in Figure 2 shown).

[0173] FnCpf1

[0174] The results obtained using FnCpf1 nuclease showed the expected results. Plates containing kanamycin antibiotic showed a similar number of growing E. coli colonies as the negative control (NC) because the cells were still resistant to kanamycin because the resistance gene was located on the CRISPR / gRNA-Ec vector that was not targeted by the gRNA. In contrast, plates containing ampicillin and kanamycin showed a strong reduction in colonies (>99%) compared to the negative control because the vector containing the ampicillin resistance gene (CRISPR / FnCpf1-Ec) was targeted and depleted by the FnCpf1 nuclease.

[0175] BEC10

[0176] Surprisingly, the results obtained using the BEC10 nuclease showed a different growth pattern. Plates containing kanamycin antibiotics and plates containing ampicillin and kanamycin antibiotics showed a strong reduction in colonies (>99%) compared to the negative control. As described for the FnCpf1 experiment, a reduction in colonies was expected on plates containing ampicillin and kanamycin (targeting / depletion of vectors containing ampicillin). In addition, plates containing only kanamycin did not show a reduction in colonies when using the FnCpf1 nuclease, but showed a strong reduction in colonies when using the BEC10 nuclease.

[0177] in conclusion

[0178] The explanation for these significant differences between the results for BEC10 and FnCpf1 is the novel mode of action of the BEC family nucleases: the spacer sequence on the vector (incorporated into the gRNA) binds specifically to the initial sequence of the pre-spacer region (target region) to activate the BEC nuclease and trigger non-specific targeting of double-stranded DNA. Thus, the DNA-targeting activity of the BEC nuclease (once specifically activated) degrades dsDNA and is able to "jump" to other DNA strands inside the same cell. This is a type of reaction that can be described as a paralogous activity, because once the nuclease is activated, even DNA without a target region will be degraded.

[0179] In the experiments shown, the BEC nuclease is activated by a protospacer sequence located on the CRISPR / BEC10-Ec vector, and once activated, the activity "jumps" across and targets the CRISPR / gRNA-Ec and / or E. coli genome, resulting in a strong reduction in colonies on plates containing only kanamycin.

[0180] To our knowledge, nucleases that are specifically activated by spacer / prospacer pairing and have paralogous dsDNA cleavage activity once activated have never been described before. This novel mode of activity can be used in various applications where classical CRISPR nucleases are non-functional or have limited applicability (e.g., Examples 3 and 5).

[0181] Embodiment 3:

[0182] Precise genome editing in Pichia pastoris using BEC10 nuclease compared with SpCas9

[0183] To demonstrate one of the advantages of the novel mode of action of the BEC family nucleases, genome editing experiments were performed in organisms naturally capable of non-homologous end joining (NHEJ) DNA repair.

[0184] Experimental setup:

[0185] In this example, the CRISPR / BEC10-Pp or CRISPR / SpCas9-Pp vector system and the HDR template were used to knock out the Ade2 gene in Pichia pastoris.

[0186] Ade2 is a non-essential gene in Pichia pastoris, but knockout results in a red phenotype of the colonies because mutant cells accumulate red purine precursors in their vacuoles (Ugolini et al., Curr Genet (2006), 485-92). Due to this easy readout, knockout of the Ade2 gene can be used as a screening system to monitor the ability of CRISPR Cas proteins to be used as genome editing tools.

[0187] In this method, knockout of the Ade2 gene was used to monitor the genome editing activity of the BEC10 nuclease compared to SpCas9 in two experimental settings.

[0188] 1. Ade2 knockout via NHEJ (without using HDR template)

[0189] 2. Specific Ade2 knockout using homology-directed repair (introduction of the HDR template results in site-specific deletion of the Ade2 gene, also eliminating the PAM and protospacer sequences)

[0190] In summary, CRISPR / BEC10-Pp or CRISPR / SpCas9-Pp expression constructs were transformed into Pichia pastoris cells with or without homology-directed repair templates and plated as described in Example 1.6.

[0191] Meanwhile, negative control experiments using CRISPR / BEC10-Pp or CRISPR / SpCas9-Pp expression constructs lacking the spacer sequence targeting the Ade2 gene were performed to demonstrate the dependency of the Cas protein on being guided to the target DNA region by a specific spacer.

[0192] After transformation and incubation for 48 hours at 30°C, the plates were analyzed by counting the number of grown colonies and by assessing their phenotype (red or white).

[0193] result:

[0194] All experiments were performed in 5 biological replicates, and the results obtained from these replicates were combined to evaluate the genome editing activity of BEC10 compared to SpCas9 (exemplary plates are shown in Figure 2A). Figure 3 shown).

[0195] In the first experimental setup, CRISPR / BEC10-Pp or CRISPR / SpCas9-Pp expression constructs were transformed into Pichia pastoris cells without the use of an HDR template (-HDR). Active SpCas9 and BEC10 nucleases resulted in a strong colony reduction (>99%) compared to the negative control experiment, with even stronger colony reduction when BEC10 nuclease was used. In addition, compared to cells treated with BEC10 nuclease in which 0% of the cells showed a red phenotype, in the experimental approach using Cas9 nuclease, ≈40% of the remaining cells showed a red (Ade2 knockout) phenotype.

[0196] In the second experimental setting, CRISPR / BEC10-Pp or CRISPR / SpCas9-Pp expression constructs were transformed into Pichia pastoris cells together with HDR templates (+HDR). Compared with the negative control experiment, active SpCas9 and BEC10 nucleases resulted in a strong colony reduction (>98%), which was a slightly less significant reduction in the overall cell number compared to the experiment without HDR template. In addition, for SpCas9 and BEC10, most surviving cells showed an Ade2 knockout phenotype (SpCas9≈73% / BEC10≈90%). In addition, 40 colonies (20 SpCas9-treated and 20 BEC10-treated) showing an Ade2 knockout phenotype were further analyzed by Sanger sequencing, showing that 14 of the 20 colonies treated with Cas9 had incorporated the HDR template into their genomes, and 6 were edited by NHEJ. In contrast, 20 out of 20 colonies analyzed after BEC10 treatment showed incorporation of the HDR template to the Ade2 gene into their genome.

[0197] in conclusion:

[0198] Although both SpCas9 and BEC nucleases resulted in significant overall colony reductions following activation, Ade2 gene editing showed clearly different outcomes between the two nucleases.

[0199] Because Pichia pastoris is an organism inherently capable of repairing DNA double-strand breaks using NHEJ, targeting of the Ade2 gene using SpCas9 resulted in Ade2 knockout colonies due to frameshift mutations caused by faulty NHEJ machinery. In contrast, cells treated with BEC10 nuclease did not show Ade2 knockout colonies, which can be explained by the novel mode of action of BEC family nucleases. BEC family nucleases exhibit a completely different mode of action that prevents NHEJ, as activation of BEC nucleases induces paralogous dsDNA activity, leading to cell death without giving cells the opportunity to prevent death through NHEJ-derived DNA repair.

[0200] In contrast, when the HDR template was used to knock out the gene, there were Ade2 knockout colonies for SpCas9 and BEC10. For SpCas9, the dsDNA break introduced inside the Ade2 gene forced the cell to repair the break. To do this, the cell had two options: A: introduce an HDR template, or B: use NHEJ to repair the DNA break. Because Pichia pastoris prefers homology-directed repair rather than NHEJ, ≈70% of the edited cells introduced the HDR template into their genome and ≈30% of the edited cells performed NHEJ-mediated DNA repair.

[0201] In contrast, once the BEC nuclease is activated, the BEC10 nuclease prevents the cell from performing NHEJ-mediated DNA repair by killing the cell. Therefore, the BEC10 nuclease forces the cell to introduce the HDR template into its genome before the BEC nuclease is activated. Because the PAM and pre-spacer sequences within the genome are deleted by integrating the HDR template, the pre-spacer sequence that matches the spacer sequence of the BECgRNA is no longer present in the genome, and the BEC nuclease remains inactive. Those cells in which the HDR template is integrated into the genome and the BEC nuclease remains inactive are able to survive the treatment, explaining why 100% of BEC-edited cells incorporate the HDR template into their genome.

[0202] Outlook:

[0203] Most higher organisms (eukaryotes) can perform NHEJ.Using genome editing tools, this mechanism can be used to knock out the gene of interest in a rather non-specific manner (introducing insertion and deletion (indel) by the NHEJ repair mechanism of error).However, once it is related to accurately knock out or knock in using HDR templates, NHEJ mechanisms just cause many technical problems, because a part of edited cells will use NHEJ pathways to repair its DNA instead of introducing HDR templates, thus resulting in a mixed cell population with undesirable editing.This limitation can be overcome using BEC family nucleases, because BEC nucleases show a novel mode of action of targeting dsDNA, which inhibits cells from performing NHEJ to withstand the ability of DNA double-strand breaks.In addition, cells are forced to introduce HDR templates into their genomes to prevent cell death, resulting in a very effective way of accurately knocking out or knocking in using BEC nucleases.

[0204] Example 4: Expression and purification of BEC10 RNP for HEK cell transfection

[0205] 4.1 CRISPR / BEC-FLAG-Ec and CRISPR / gRNA-Ec for BEC expression (E. coli) and RNP purification Vector system

[0206] The necessary genetic elements for inducible expression and FLAG tag purification of BEC10 nuclease and for constitutive expression of guide RNA (gRNA) transcripts are provided on three separate vectors (CRISPR / BEC10-FLAG-Ec, CRISPR / gRNA-EGFP-Ec, and CRISPR / gRNA-NC-Ec). Design of CRISPR / BEC-FLAG-Ec protein expression vector

[0207] Using the bioinformatics application provided by gene synthesis provider GeneArt (Thermo Fisher Scientific, Regensburg, Germany), the synthesized 3696bp BEC10 nucleotide sequence is codon optimized for expression in Escherichia coli BW25113. For protein expression, the resulting synthetic gene is fused to inducible araC-ParaBAD inducible promoter system and fdT terminator (Otsuka & Kunisawa, Journal of Theoretical Biology 97 (1982), 415-436). In addition, the DNA nuclease encoding sequence is extended 3' by the sequence encoding nucleoplasmin (nucleoplasmin) nuclear localization signal (NLS) and two SV40NLS. At the 5' end of the DNA nuclease encoding sequence, the sequence is extended by the sequence encoding mycNLS. For the purification of DNA nuclease, the FLAG tag is connected to the 5' encoding sequence of myc NLS to DNA nuclease by a joint.

[0208] The final BEC10_E. coli protein expression cassette was inserted by Gibson Assembly Cloning (NEB, Frankfurt, Germany) into an E. coli shuttle vector containing all necessary genetic elements for episomal propagation and selection of recombinant E. coli cells.

[0209] CRISPR / BEC10-FLAG-Ec Vector System

[0210] The complete nucleotide sequence of the constructed CRISPR / BEC10-FLAG-Ec vector system is provided as SEQ ID NO: 31.

[0211] Guide RNA (gRNA) expression vector for EGFP targeting (CRISPR / gRNA-EGFP-Ec) and negative controls (CRISPR / gRNA-NC-Ec) design

[0212] The design of the gRNA expression vector was as described in Example 1.1. In contrast to the vector described in 1.1, the spacer sequence targeting the kanamycin gene was exchanged for the spacer sequence targeting the EGFP gene (SEQ ID NO: 32) or the negative control (NC) sequence (SEQ ID NO: 33) that did not match any target region in the HEK cells used.

[0213] The complete nucleotide sequence of the constructed CRISPR / gRNA-EGFP-Ec vector system is provided as SEQ ID NO: 34.

[0214] The complete nucleotide sequence of the constructed CRISPR / gRNA-NC-Ec vector system is provided as SEQ ID NO: 35.

[0215] Nuclease expression

[0216] In brief, a single colony of E. coli BW25113+CRISPR / BEC10-FLAG-Ec+CRISPR / gRNA-EGFP-Ec for BEC10-EGFP RNP expression or E. coli BW25113+CRISPR / BEC10-FLAG-Ec+CRISPR / gRNA-NC-Ec for BEC10-NC RNP expression was inoculated in 5 ml LB-Kan-Amp medium and incubated at 37°C for 12 to 14 hours at 200 rpm on a horizontal shaker. The pre-culture grown overnight was diluted into a fresh 60 ml LB medium to an optical density (OD600) of 0.05 at 600 nm. The inoculated medium was incubated at 30°C on a horizontal shaker at 200 rpm until the culture reached an optical density of 0.2 at OD600. The incubation temperature was reduced to 21°C. At an optical density OD600 of 0.5, 600 μl of 20% L-arabinose was added and the cells were incubated at 200 rpm at 21° C. for about 21 hours until the culture reached an optical density at OD600 of 4. The culture was transferred to a 50 ml conical tube and the cells were harvested by centrifugation at 4° C. for 10 minutes and 4000×g. The pelleted cells from the 90 ODV culture were stored at −20° C.

[0217] Cell disruption and FLAG tag purification

[0218] The 90ODV pelleted cells were resuspended in 3 ml TBS (50 mM TRIS-HCl, 150 mM NaCl, pH 7,4) and disrupted by ultrasonic cell disruption using a Branson Sonifier 250 with four ultrasonic cycles of 50% duty cycle, 2.5 output for 30 seconds. Between each cycle, the cells were cooled on ice for 1 minute. The soluble fraction was separated from the insoluble fraction by centrifugation at 4°C for 10 minutes and 4500 rpm.

[0219] Nuclease and gRNA (already coupled to each other) were prepared by Pierce TM Magnetic anti-DYKDDDDK-agarose (ThermoFisher Scientific, Regensburg, Germany) purification. 120μl magnetic beads aliquots were used for the purification of 1.5ml soluble cell fraction. The magnetic beads were balanced twice with 1ml TBS buffer (50mM Tris-HCl pH7.5, 150mM NaCl). The supernatant was removed using a magnetic stand. 1.5ml soluble fraction was incubated with magnetic beads on a rotator at 4°C for 18-20 hours. After binding, the magnetic beads were washed 4 times with 1ml TBS buffer (50mM Tris-HCl pH7.5, 150mM NaCl), and washed once with 1ml of LC-MS analytical water (TH Goyer, Lunningen, Germany), and the supernatant was removed in a magnetic stand. The supernatant was removed by adding 50μl 1.5mg / ml Pierce dissolved in dPBS (PAN Biotech, Aidenbach, Germany). TM The nuclease / gRNA complex was eluted from the beads with 3×DYKDDDK-peptide (ThermoFisher Scientific, Regensburg, Germany) and incubated on a rotator for 30 min at room temperature. The supernatant containing purified BEC10-EGFP or BEC10-NC ribonucleoprotein (RNP) was removed from the beads in a magnetic stand and stored at 4°C.

[0220] HEK-EGFP and HEK-DsRed cell generation

[0221] To generate two types of HEK cells, commercially available Flp-In TM T-REx TM 293 cell line (ThermoFisher) and Flp-In TM T-REx TM Core Kit (Thermo Fisher) was used in combination. To integrate the gene of interest, follow the same procedure as for Flp-In TM T-REx TMAccording to the instructions provided with the core kit, a DNA fragment containing the coding sequence of EGFP (enhanced green fluorescent protein) (SEQ ID NO: 36) or DsRed (red fluorescent protein) (SEQ ID NO: 37) is locus-specifically integrated into the Flp-In TM T-REx TM The genome of 293 cells was modified to result in two identical cell lines that differed only by the inserted gene (HEK-EGFP and HEK-DsRed).

[0222] HEK cell transfection and culture

[0223] Cells were seeded and cultured in culture medium (DMEM, 8% FCS without tetracycline, 4 mM L-glutamine; PAN Biotech, Aidenbach, Germany, #P04-03600, #P30-3602, #P04-80100) + 1 μg / ml tetracycline (Merck KGaA, Darmstadt, Germany, #T7660) (to induce the expression of EGFP and DsRed genes) to reach 70% to 90% confluency on the day of transfection. 2+ and Mg 2 ; PAN Biotech, Aidenbach, Germany, #P04-53500), the cells were detached by adding 1 ml of pre-warmed TrypLE (Thermo Fisher Scientific, Regensburg, Germany) to a 10 cm culture dish and incubated at 37°C for 2 minutes. After adding 5 ml of pre-warmed culture medium, the cell number of the suspension was determined using a CASY cell counter (OLS OMNI Life Science GmbH & Co KG, Bremen, Germany). 1×10 5 Transfer 10 cells to a 5 ml conical tube and centrifuge at room temperature for 5 min and 200 g. Remove the supernatant and resuspend the pelleted cells in 1 ml 1× DPBS (without Ca). 2+ and Mg 2+ ) and centrifuged at room temperature for 5 minutes and 200 g. TM 10 μl kit (Thermo Fisher Scientific, Regensburg, Germany) with Neon TMTransfection system (Thermo Fisher Scientific, Regensburg, Germany) was used for electroporation, the supernatant was removed again, and the cells were resuspended in 10 μl of resuspension buffer R containing 50 pmol of purified BEC10-EGFP or BEC10-NC RNP. Then, 10 μl of Neon TM Aspirate the cell-RNP suspension with a transfection tip and transfer it to a Neon flask containing 3 ml of electrolysis buffer E. TM The cells were then electroporated with a single pulse of 1600 V and 20 ms pulse width. The transfected cells were plated in a 24-well plate containing 1× Gibco TM Antibiotic / antimycotic solution (Thermo Fisher Scientific, Regensburg, Germany) and 15 μg / ml Gibco TM 500 μl of pre-warmed (37° C.) medium containing gentamicin (Thermo Fisher Scientific, Regensburg, Germany) was incubated at 37° C. and 5% CO 2 . After 24 hours of incubation, 1 μg / ml tetracycline was added to the medium.

[0224] After reaching approximately 70% to 90% confluence, transfected cells in 24 wells were detached using pre-warmed (37°C) TrypLE and transferred to 10 cm culture dishes and cultured for another 5 days in culture medium + 1 μg / ml tetracycline (the culture medium was changed after 3 days of culture) and then visually evaluated by bright field and fluorescence (EGFP = Exλ488nm, Emλ507nm / DsRed = Exλ558nm, Emλ583) microscopy (Leica DM Il LED-Leica Microsystems GmbH, Wetzlar, Germany) and flow cytometry cell counting (Cy Flow Space-Symex Deutschland GmbH, Norderstedt, Germany). FACS (fluorescence activated cell sorting) analysis

[0225] The cells were rinsed with 5 ml of 1×DPBS and detached with 1 ml of TrypLE at 37°C for 10 min. To stop the detachment process, 9 ml of DMEM was added and the cell number was determined by CASY cell counter. After transferring the cell suspension to a 50 ml conical tube, the cells were pelleted by centrifugation at 200 g for 5 min at room temperature and then resuspended in 1×DPBS in an appropriate volume to adjust the cell number to 1×10 6The cell suspension was then visually analyzed by FACS (CyFlow Space—Sysmex Deutschland GmbH, Norderstedt, Germany) to evaluate the EGFP staining of the cells according to the instructions provided by the manufacturer.

[0226] Example 5: Target-Specific Cell Depletion of Mammalian Cells

[0227] To demonstrate the utility of BEC family nucleases in application areas where classical CRISPR nucleases cannot be applied, experiments were performed showing that BEC10 induces depletion in mammalian cells based on specific target regions.

[0228] Experimental setup:

[0229] To demonstrate cell-specific depletion using the novel mode of action of the BEC family nucleases (paralogous activity following initial, guide-specific activation), experiments were performed using a 50 / 50 mixture of two types of HEK cells (HEK-EGFP and HEK-DsRed). Both types of HEK cells were nearly identical Flp-In TM T-REx TM 293 cells. A 50 / 50 mixture of the two cell types was cultured as described in Example 4, and the BEC10 nuclease combined with a spacer sequence that specifically binds to a region in the EGFP gene (and does not match the rest of the genome or the DsRed gene) was transfected into the cells as described in Example 4. After culturing the cell mixture for 7 days, the cells were visually evaluated using microscopy (bright field and fluorescence) and counted by FACS to demonstrate specific cell depletion of cells carrying EGFP without affecting the viability of cells carrying DsRed.

[0230] In parallel, negative control experiments using BEC10 nuclease in combination with a spacer sequence that does not bind to any sequence in HEK-EGFP or HEK-DsRed cells were performed to demonstrate the dependence of guide-specific BEC10 activation for targeted cell depletion.

[0231] result:

[0232] All experiments were performed in 6 biological replicates, and the results obtained from these replicates were combined to evaluate the cellular depletion efficiency of BEC10 nuclease. Exemplary microscopy images and FACS results are shown in Figure 4 .

[0233] After 7 days of culture, a 50 / 50 mixture of HEK-EGFP and HEK-DsRed cells was evaluated by microscopy (bright field and fluorescence) and FACS counting.

[0234] Negative control experiments using BEC10-NC RNP (BEC10 nuclease combined with a spacer sequence that does not match the sequence from HEK-EGFP or HEK-DsRed cells) showed normal cell growth on plates ( Figure 4 A Top image) (About half of the growing cells showed EGFP staining ( Figure 4 A middle image), and the other half shows DsRed staining ( Figure 4 A bottom image). To support this visual assessment, FACS counts of growing colonies of negative controls ( Figure 4 C upper graph) shows that ≈55% of the counted cells were confirmed as EGFP-negative (peak on the left side of the graph), and ≈45% were EGFP-positive (peak on the right side of the graph) cells, confirming that the 50 / 50 mixture of the two cell types in this negative control setting did not change significantly throughout the seven days of culture.

[0235] BEC-specific cell depletion experiments using BEC10-EGFP RNP (BEC10 nuclease combined with a spacer sequence specifically matching a sequence from the EGFP gene) showed a significant reduction in growing cells after 7 days compared to negative controls ( Figure 4 B The upper image and Figure 4 A upper image), indicating the depletion of cells during the 7-day cell growth period. In addition, the fluorescent image revealed that only two cells in the field of view showed EGFP staining ( Figure 4 B middle image), showing strong depletion of HEK-EGFP positive cells, while viability of HEK-DsRed cells ( Figure 4 B bottom image) remained unaffected by BEC10 treatment (almost all growing cells showed DsRed staining). FACS counting also supported these results, as the right peak (showing EGFP-positive cells) almost completely disappeared, while the left peak showed a strong signal for EGFP-negative cells. Further evaluation of the FACS results showed that less than 1.5% of the total cell population was EGFP-positive and greater than 98.5% was EGFP-negative, confirming the specific cell depletion of EGFP-positive cells.

[0236] in conclusion:

[0237] The Examples demonstrate the use of the novel and unique mode of action of the BEC family nucleases for target-specific depletion of mammalian cells.

[0238] Non-homologous end joining (NHEJ) is the preferred DNA repair mechanism in most higher eukaryotic cells, such as mammalian and plant cells, meaning that DNA double-strand breaks introduced by classical CRISPR nucleases will be repaired by the NHEJ mechanism, often resulting in short indels (insertions or deletions), allowing the cell to survive the DNA damage.

[0239] In contrast, BEC family nucleases induce paralogous dsDNA degradation after initial, guide-specific activation, overcharging the repair mechanisms of target cells and leading to cell death. Due to the PAM and spacer sequence-specific initial activation of BEC family nucleases, this novel mode of action can be used to selectively deplete all cells carrying a marker sequence without affecting the viability of surrounding cells that do not carry this specific sequence.

[0240] In the future, this novel and unique mode of action could be exploited for various application areas such as target-specific depletion of prokaryotic and eukaryotic cells, including, for example, cancer, autoreactive immune or virally infected cells, as well as enrichment of classical genome editing events by subsequent depletion of all non-edited cells.

Claims

1. A method for genome editing a cell at a target locus by homology directed repair (HDR) within a cell population and simultaneously enriching for HDR genome-edited cells within the cell population, wherein the method comprises: (A) introducing the following into cells within a cell population: One or more nucleic acid molecules encoding, in an expressible form: (i) a CRISPR nuclease comprising or consisting of: (a) the amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence that is at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence that is at least 80% identical to the nucleotide sequence of (b), (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus and (b) a second segment that interacts with the CRISPR nuclease of (i), and A nucleic acid molecule comprising, consisting of or encoding: (iii) a donor template having homology to the target locus; or (A') introducing the following into cells within the cell population: (i) a CRISPR nuclease comprising or consisting of: (a) the amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence that is at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence that is at least 80% identical to the nucleotide sequence of (b), A nucleic acid molecule encoding, in an expressible form: (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus and (b) a second segment that interacts with the CRISPR nuclease of (i), and A nucleic acid molecule comprising, consisting of or encoding: (iii) a donor template having homology to the target locus; or (A") introducing the following into cells within the cell population: (i) a ribonucleoprotein complex (RNP) comprising or consisting of: A CRISPR nuclease comprising or consisting of: (a) the amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence that is at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence that is at least 80% identical to the nucleotide sequence of (b), The CRISPR nuclease is complexed with a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus and (b) a second segment that interacts with the CRISPR nuclease; and A nucleic acid molecule comprising, consisting of or encoding: (ii) a nucleic acid molecule encoding, in an expressible form, a donor template having homology to the target locus; and (B) Cells are cultured under conditions in which a target locus of cells of a cell population becomes genome-edited via homology directed repair (HDR) and CRISPR nuclease simultaneously enriches for HDR genome-edited cells within the cell population.

2. The method according to claim 1, wherein the method further comprises: (C) Isolating one or more cells in which the target locus has been genome edited by homology directed repair (HDR).

3. The method of claim 1 or 2, wherein the donor template introduces more than one mutation at the target locus.

4. The method of any one of claims 1 to 3, wherein the donor template inserts more than one nucleotide at the target locus.

5. The method of any one of claims 1 to 4, wherein the donor template has more than one nucleotide deleted at the target locus.

6. The method of any one of claims 1 to 5, wherein the donor template replaces more than one nucleotide at the target locus.

7. The method according to any one of claims 1 to 6, wherein the donor template comprises or consists of a nucleotide sequence having one or more desired mutations flanked by nucleotide sequences homologous to the target locus.

8. A method for selectively depleting cells comprising a target locus within a cell population, wherein the method comprises: (A) introducing one or more nucleic acid molecules into cells within a cell population, wherein the one or more nucleic acid molecules encode, in an expressible form: (i) a CRISPR nuclease comprising or consisting of: (a) the amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence that is at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence that is at least 80% identical to the nucleotide sequence of (b), and (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus and (b) a second segment that interacts with the CRISPR nuclease of (i); or (A') introducing the following into cells within the cell population: (i) a CRISPR nuclease comprising or consisting of: (a) the amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence that is at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence that is at least 80% identical to the nucleotide sequence of (b), and one or more nucleic acid molecules encoding, in an expressible form: (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus and (b) a second segment that interacts with the CRISPR nuclease of (i); or (A") introducing the following into cells within the cell population: (i) ribonucleoprotein complex (RNP), It includes or consists of the following: (a) the amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence that is at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence that is at least 80% identical to the nucleotide sequence of (b), complexed with a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus and (b) a second segment that interacts with a CRISPR nuclease; and (B) Cells are cultured under conditions where the CRISPR nuclease selectively depletes cells within a population of cells containing the target locus.

9. The method of any one of claims 1 to 8, wherein the cells within the population are capable of repairing double-stranded DNA breaks by non-homologous end joining (NHEJ).

10. The method according to any one of claims 1 to 9, wherein the cells within the population are prokaryotic cells or eukaryotic cells, preferably vertebrate cells, and most preferably mammalian cells.

11. The method according to any one of claims 1 to 10, wherein the method is an in vitro or ex vivo method.

12. (A) one or more nucleic acid molecules encoding, in an expressible form: (i) a CRISPR nuclease comprising or consisting of: (a) the amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence that is at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence that is at least 80% identical to the nucleotide sequence of (b), and (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus; and (a) a second segment that interacts with the CRISPR nuclease of (i); or (A')(i) A CRISPR nuclease comprising or consisting of: (a) the amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence that is at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence that is at least 80% identical to the nucleotide sequence of (b), and one or more nucleic acid molecules encoding, in an expressible form: (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus; and (a) a second segment that interacts with the CRISPR nuclease of (i); or (A") a ribonucleoprotein complex (RNP) comprising or consisting of: (a) the amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence that is at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence that is at least 80% identical to the nucleotide sequence of (b), complexed with a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus; and (a) a second segment that interacts with a CRISPR nuclease, It is used to treat disease by selectively depleting cells containing target loci associated with the disease to be treated.

13. A vector comprising in an expressible form: (i) a CRISPR nuclease comprising or consisting of: (a) the amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence that is at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence that is at least 80% identical to the nucleotide sequence of (b), (ii) a guide RNA comprising (a) a first segment comprising a nucleotide sequence complementary to a sequence at a target locus; and (a) a second segment that interacts with the CRISPR nuclease of (i), and (iii) Optionally, a donor template having homology to the target locus.

14. Use of a CRISPR nuclease for genome editing of cells at a target locus by homology directed repair (HDR) within a cell population and simultaneously enriching for HDR genome-edited cells within the cell population, and / or for selectively depleting cells comprising a target locus within a cell population, The CRISPR nuclease comprises or consists of: (a) the amino acid sequence of any one of SEQ ID NO: 1, 2 or 3; (b) an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 4, 5, 6 or 7; (c) an amino acid sequence that is at least 80% identical to the amino acid sequence of (a), or (d) an amino acid sequence encoded by a nucleic acid sequence that is at least 80% identical to the nucleotide sequence of (b).

15. The method according to any one of claims 1 to 11, the one or more nucleic acid molecules for use according to claim 12, or the CRISPR nuclease and guide RNA, or the RNP, the vector according to claim 13 or the use according to claim 14, wherein the at least 80% sequence identity is at least 85%, preferably at least 90%, and most preferably at least 95%.